DRK3DanielKuritzkesDaniel Robert Kuritzkes, M.D.42.36070000000000-71.1009000000000062664Kuritzkes, DanielRobert617/768-8373Harriet Ryan Albee Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson9820578Demeter LM, D'Aquila R, Weislow O, Lorenzo E, Erice A, Fitzgibbon J, Shafer R, Richman D, Howard TM, Zhao Y, Fisher E, Huang D, Mayers D, Sylvester S, Arens M, Sannerud K, Rasheed S, Johnson V, Kuritzkes D, Reichelderfer P, Japour AJournal of virological methodsInterlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virol Methods. 1998 Nov; 75(1):93-104.J Virol Methods1998-11-01T00:00:001998Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.10397563Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli CAIDS (London, England)Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. AIDS. 1999 Apr 16; 13(6):685-94.AIDS1999-04-16T00:00:001999Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.Authorship 10455617Authorship 10463951629474268Quercia R, Perno CF, Koteff J, Moore K, McCoig C, St Clair M, Kuritzkes DJournal of acquired immune deficiency syndromes (1999)Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):125-135.J Acquir Immune Defic Syndr2018-06-01T00:00:002018Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.29470552Hogan LE, Vasquez J, Hobbs KS, Hanhauser E, Aguilar-Rodriguez B, Hussien R, Thanh C, Gibson EA, Carvidi AB, Smith LCB, Khan S, Trapecar M, Sanjabi S, Somsouk M, Stoddart CA, Kuritzkes DR, Deeks SG, Henrich TJPLoS pathogensIncreased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathog. 2018 02; 14(2):e1006856.PLoS Pathog2018-02-22T00:00:002018Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.Authorship 103277915115831Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DRThe New England journal of medicineTriple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004 Apr 29; 350(18):1850-61.N Engl J Med2004-04-29T00:00:002004Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.19266092Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RWPloS oneDrug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009; 4(3):e4724.PLoS One2009-03-06T00:00:002009Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.29593048Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZJournal of virologyEffect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. J Virol. 2018 06 15; 92(12).J Virol2018-05-29T00:00:002018Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.Authorship 105566599780274Young B, Johnson S, Bahktiari M, Shugarts D, Young RK, Allen M, Ramey RR, Kuritzkes DRThe Journal of infectious diseasesResistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis. 1998 Nov; 178(5):1497-501.J Infect Dis1998-11-01T00:00:001998Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure.10068574Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MMThe Journal of infectious diseasesCharacterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999 Apr; 179(4):799-807.J Infect Dis1999-04-01T00:00:001999Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.Authorship 1056472129617815Kuritzkes DRThe Journal of infectious diseasesResistance to Dolutegravir-A Chink in the Armor? J Infect Dis. 2018 07 24; 218(5):673-675.J Infect Dis2018-07-24T00:00:002018Resistance to Dolutegravir-A Chink in the Armor?8615036Li QX, Camerini D, Xie Y, Greenwald M, Kuritzkes DR, Chen ISVirologySyncytium formation by recombinant HTLV-II envelope glycoprotein. Virology. 1996 Apr 01; 218(1):279-84.Virology1996-04-01T00:00:001996Syncytium formation by recombinant HTLV-II envelope glycoprotein.11559422Wu H, Connick E, Kuritzkes DR, Landay A, Spritzler J, Zhang B, Spear GT, Kessler H, Lederman MMAIDS research and human retrovirusesMultiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 01; 17(13):1231-40.AIDS Res Hum Retroviruses2001-09-01T00:00:002001Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.12195374McFarland EJ, Harding PA, Striebich CC, MaWhinney S, Kuritzkes DR, Kotzin BLThe Journal of infectious diseasesClonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children. J Infect Dis. 2002 Aug 15; 186(4):477-85.J Infect Dis2002-08-02T00:00:002002Clonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children.14624369Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, O'Neil D, Schock B, Kuritzkes D, Lederman MMThe Journal of infectious diseasesImmune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2003 Nov 15; 188(10):1444-54.J Infect Dis2003-11-13T00:00:002003Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.20634701Hu Z, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr. 2010 Oct; 55(2):148-55.J Acquir Immune Defic Syndr2010-10-01T00:00:002010Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.19106428Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the Drug Resistance Mutations in HIV-1. Top HIV Med. 2008 Dec; 16(5):138-45.Top HIV Med2008-12-01T00:00:002008Update of the Drug Resistance Mutations in HIV-1.19864933Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola DAIDS (London, England)Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. AIDS. 2010 Jan 28; 24(3):365-71.AIDS2010-01-28T00:00:002010Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.19904402Alyassin MA, Moon S, Keles HO, Manzur F, Lin RL, Hæggstrom E, Kuritzkes DR, Demirci ULab on a chipRapid automated cell quantification on HIV microfluidic devices. Lab Chip. 2009 Dec 07; 9(23):3364-9.Lab Chip2009-09-30T00:00:002009Rapid automated cell quantification on HIV microfluidic devices.20458804Kuritzkes DRJournal watch. AIDS clinical careReport from the XVIII International HIV Drug Resistance Workshop. J Watch AIDS Clin Care. 2009 Oct; 21(10):85-6.J Watch AIDS Clin Care2009-10-01T00:00:002009Report from the XVIII International HIV Drug Resistance Workshop.19874179Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JDThe Journal of infectious diseasesResponse to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis. 2009 Dec 01; 200(11):1724-8.J Infect Dis2009-12-01T00:00:002009Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.22162985Kuritzkes DRCurrent opinion in virologyDrug resistance in HIV-1. Curr Opin Virol. 2011 Dec; 1(6):582-9.Curr Opin Virol2011-12-01T00:00:002011Drug resistance in HIV-1.17357053Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman KL, Gulick RMThe Journal of infectious diseasesPlasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007 Apr 15; 195(8):1169-76.J Infect Dis2007-03-06T00:00:002007Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.Authorship 106501611Authorship 10644361329746555Hogan LE, Hanhauser E, Hobbs KS, Palmer CD, Robles Y, Jost S, LaCasce AS, Abramson J, Hamdan A, Marty FM, Kuritzkes DR, Henrich TJPloS oneHuman Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. PLoS One. 2018; 13(5):e0197298.PLoS One2018-05-10T00:00:002018Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation.29767504Draz MS, Lakshminaraasimulu NK, Krishnakumar S, Battalapalli D, Vasan A, Kanakasabapathy MK, Sreeram A, Kallakuri S, Thirumalaraju P, Li Y, Hua S, Yu XG, Kuritzkes DR, Shafiee HACS nanoMotion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone. ACS Nano. 2018 06 26; 12(6):5709-5718.ACS Nano2018-05-16T00:00:002018Motion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone.16995272Kuritzkes DRAIDS clinical careReport from the XV International HIV Drug Resistance Workshop. AIDS Clin Care. 2006 Sep; 18(9):83-4.AIDS Clin Care2006-09-01T00:00:002006Report from the XV International HIV Drug Resistance Workshop.17243065Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RMClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaHIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007 Feb 15; 44(4):591-5.Clin Infect Dis2007-01-17T00:00:002007HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.17415036Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DRAIDS (London, England)Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23.AIDS2007-04-23T00:00:002007Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.18627268Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008 Aug 15; 47(4):542-53.Clin Infect Dis2008-08-15T00:00:002008Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.20662716Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard R, Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock BThe Journal of infectious diseasesAIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010 Sep 01; 202(5):705-16.J Infect Dis2010-09-01T00:00:002010AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.20936980Henrich TJ, Li JZ, Felsenstein D, Kotton CN, Plenge RM, Pereyra F, Marty FM, Lin NH, Grazioso P, Crochiere DM, Eggers D, Kuritzkes DR, Tsibris AMThe Journal of infectious diseasesXenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis. 2010 Nov 15; 202(10):1478-81.J Infect Dis2010-10-11T00:00:002010Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions.21555822Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby MAntiviral therapyBaseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir Ther. 2011; 16(3):395-404.Antivir Ther2011-01-01T00:00:002011Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.21791652Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJThe Journal of infectious diseasesAntiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011 Aug 15; 204(4):515-20.J Infect Dis2011-08-15T00:00:002011Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.22479542Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley RT, Kuritzkes DRPloS oneCharacteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012; 7(3):e34134.PLoS One2012-03-30T00:00:002012Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.Authorship 10703201429852062Ibrahim M, Maswabi K, Ajibola G, Moyo S, Hughes MD, Batlang O, Sakoi M, Auletta-Young C, Vaughan L, Lockman S, Jean-Philippe P, Yu X, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro RLJournal of the International AIDS SocietyTargeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana. J Int AIDS Soc. 2018 05; 21(5):e25111.J Int AIDS Soc2018-05-01T00:00:002018Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana.23446628Li JZ, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaClinical implications of HIV-1 minority variants. Clin Infect Dis. 2013 Jun; 56(11):1667-74.Clin Infect Dis2013-02-27T00:00:002013Clinical implications of HIV-1 minority variants.15937768Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAccuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin Infect Dis. 2005 Jul 01; 41(1):92-9.Clin Infect Dis2005-05-24T00:00:002005Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).10479129Brown AJ, Günthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DDThe Journal of infectious diseasesSequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. J Infect Dis. 1999 Oct; 180(4):1043-9.J Infect Dis1999-10-01T00:00:001999Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.10714563Valdez H, Smith KY, Landay A, Connick E, Kuritzkes DR, Kessler H, Fox L, Spritzler J, Roe J, Lederman MB, Lederman HM, Evans TG, Heath-Chiozzi M, Lederman MMAIDS (London, England)Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000 Jan 07; 14(1):11-21.AIDS2000-01-07T00:00:002000Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.10714565Precious HM, Günthard HF, Wong JK, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJAIDS (London, England)Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS. 2000 Jan 07; 14(1):31-6.AIDS2000-01-07T00:00:002000Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.11329066Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, Wilson CCNature medicineWhole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001 May; 7(5):625-9.Nat Med2001-05-01T00:00:002001Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity.12232846Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JFThe Journal of infectious diseasesOnce-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. J Infect Dis. 2002 Oct 01; 186(7):1028-33.J Infect Dis2002-09-13T00:00:002002Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.Authorship 10722011029921650Hogan LE, Körner C, Hobbs K, Simoneau CR, Thanh C, Gibson EA, Palmer CD, Pandit A, Marty FM, Kuritzkes DR, Jost S, Ritz J, Henrich TJBlood advancesNK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Adv. 2018 06 26; 2(12):1412-1416.Blood Adv2018-06-26T00:00:002018NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation.22772389Hirsch MS, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)The future of HIV treatment. J Acquir Immune Defic Syndr. 2012 Aug 01; 60 Suppl 2:S39-40.J Acquir Immune Defic Syndr2012-08-01T00:00:002012The future of HIV treatment.Authorship 1098461723264671Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DRThe Journal of infectious diseasesImpact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis. 2013 Mar 15; 207(6):893-7.J Infect Dis2012-12-21T00:00:002012Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.16528087Koenig SP, Kuritzkes DR, Hirsch MS, Léandre F, Mukherjee JS, Farmer PE, del Rio CBMJ (Clinical research ed.)Monitoring HIV treatment in developing countries. BMJ. 2006 Mar 11; 332(7541):602-4.BMJ2006-03-11T00:00:002006Monitoring HIV treatment in developing countries.16583266Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JGJournal of pharmacokinetics and pharmacodynamicsPharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn. 2006 Aug; 33(4):399-419.J Pharmacokinet Pharmacodyn2006-04-01T00:00:002006Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.17804858Ribaudo HJ, Kuritzkes DR, Gulick RMThe New England journal of medicineA comparison of three initial antiretroviral AIDS regimens. N Engl J Med. 2007 Sep 06; 357(10):1056-7.N Engl J Med2007-09-06T00:00:002007A comparison of three initial antiretroviral AIDS regimens.19127500Kuritzkes DRIDrugs : the investigational drugs journalDrug Therapy in HIV Infection--Ninth International Congress. IDrugs. 2009 Jan; 12(1):20-5.IDrugs2009-01-01T00:00:002009Drug Therapy in HIV Infection--Ninth International Congress.19339950Moore JP, Kuritzkes DRCurrent opinion in HIV and AIDSA pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS. 2009 Mar; 4(2):118-24.Curr Opin HIV AIDS2009-03-01T00:00:002009A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.20068260Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009 Dec; 17(5):138-45.Top HIV Med2009-12-01T00:00:002009Update of the drug resistance mutations in HIV-1: December 2009.Authorship 10813832130024859Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZThe Journal of clinical investigationHIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085.J Clin Invest2018-08-20T00:00:002018HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.17885302Paredes R, Cheng I, Kuritzkes DR, Tuomala REAIDS (London, England)High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. AIDS. 2007 Oct 01; 21(15):2103-6.AIDS2007-10-01T00:00:002007High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.23290628Henrich TJ, Kuritzkes DRCurrent opinion in virologyHIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol. 2013 Feb; 3(1):51-7.Curr Opin Virol2013-01-03T00:00:002013HIV-1 entry inhibitors: recent development and clinical use.Authorship 10874111730085241Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZThe Journal of infectious diseasesThe Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.J Infect Dis2018-11-05T00:00:002018The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.18549313Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DDClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008 Jul 15; 47(2):266-85.Clin Infect Dis2008-07-15T00:00:002008Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.19665685Kim YG, Moon S, Kuritzkes DR, Demirci UBiosensors & bioelectronicsQuantum dot-based HIV capture and imaging in a microfluidic channel. Biosens Bioelectron. 2009 Sep 15; 25(1):253-8.Biosens Bioelectron2009-06-18T00:00:002009Quantum dot-based HIV capture and imaging in a microfluidic channel.18598191Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola DThe Journal of infectious diseasesInitiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 2008 Aug 15; 198(4):470-80.J Infect Dis2008-08-15T00:00:002008Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.19964416Moon S, Keles HO, Kim YG, Kuritzkes D, Demirci UAnnual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International ConferenceLensless imaging for point-of-care testing. Annu Int Conf IEEE Eng Med Biol Soc. 2009; 2009:6376-9.Annu Int Conf IEEE Eng Med Biol Soc2009-01-01T00:00:002009Lensless imaging for point-of-care testing.20578878Schouten JT, Kmack A, Kuritzkes DR, Gulick RMClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaReply to gelinck and burger. Clin Infect Dis. 2010 Aug 1; 51(3):365-6.Clin Infect Dis2010-08-01T00:00:002010Reply to gelinck and burger.21383975Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson MPLoS pathogensEpisomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011 Feb; 7(2):e1001303.PLoS Pathog2011-02-24T00:00:002011Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.22090117Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AMJournal of virologyHIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug. J Virol. 2012 Jan; 86(2):1119-28.J Virol2011-11-16T00:00:002011HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.3882660Iuchi S, Kuritzkes DR, Lin ECJournal of bacteriologyEscherichia coli mutant with altered respiratory control of the frd operon. J Bacteriol. 1985 Mar; 161(3):1023-8.J Bacteriol1985-03-01T00:00:001985Escherichia coli mutant with altered respiratory control of the frd operon.7538548Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW, Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DRThe Journal of infectious diseasesPrevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis. 1995 May; 171(5):1172-9.J Infect Dis1995-05-01T00:00:001995Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.8553576Li QX, Camerini D, Kuritzkes DR, Chen ISVirologyRapid generation of antibodies against the HTLV-II external envelope protein by growth of mouse plasmacytomas in SCID mice. Virology. 1995 Dec 20; 214(2):680-4.Virology1995-12-20T00:00:001995Rapid generation of antibodies against the HTLV-II external envelope protein by growth of mouse plasmacytomas in SCID mice.8640545Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PANature medicineHIV viral load markers in clinical practice. Nat Med. 1996 Jun; 2(6):625-9.Nat Med1996-06-01T00:00:001996HIV viral load markers in clinical practice.22179227Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DRAIDS (London, England)Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS. 2012 Jan 14; 26(2):185-92.AIDS2012-01-14T00:00:002012Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.22252820Henrich TJ, Lewine NR, Lee SH, Rao SS, Berro R, Gulick RM, Moore JP, Tsibris AM, Kuritzkes DRAntimicrobial agents and chemotherapyDifferential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob Agents Chemother. 2012 Apr; 56(4):1931-5.Antimicrob Agents Chemother2012-01-17T00:00:002012Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.21346588Lin NH, Smeaton LM, Giguel F, Novitsky V, Moyo S, Mitchell RM, Makhema J, Essex M, Lockman S, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr. 2011 May 01; 57(1):46-50.J Acquir Immune Defic Syndr2011-05-01T00:00:002011Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana.21402549Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, Lederman MM, Carrington M, Walker BD, Schooley RT, Kuritzkes DRThe Journal of infectious diseasesFactors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis. 2011 Apr 01; 203(7):976-83.J Infect Dis2011-04-01T00:00:002011Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.15186710Kuritzkes DRAIDS patient care and STDsPreventing and managing antiretroviral drug resistance. AIDS Patient Care STDS. 2004 May; 18(5):259-73.AIDS Patient Care STDS2004-05-01T00:00:002004Preventing and managing antiretroviral drug resistance.2323931Stinson MC, Kuritzkes DR, Masse FXHealth physicsGuidelines for an effective radiation safety program in a human immunodeficiency virus (HIV) laboratory. Health Phys. 1990 Apr; 58(4):503-5.Health Phys1990-04-01T00:00:001990Guidelines for an effective radiation safety program in a human immunodeficiency virus (HIV) laboratory.18266606Kuritzkes DRThe Journal of infectious diseasesHIV-1 subtype as a determinant of disease progression. J Infect Dis. 2008 Mar 01; 197(5):638-9.J Infect Dis2008-03-01T00:00:002008HIV-1 subtype as a determinant of disease progression.Authorship 1103062930327456Draz MS, Kochehbyoki KM, Vasan A, Battalapalli D, Sreeram A, Kanakasabapathy MK, Kallakuri S, Tsibris A, Kuritzkes DR, Shafiee HNature communicationsDNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics. Nat Commun. 2018 10 16; 9(1):4282.Nat Commun2018-10-16T00:00:002018DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics.8397910McFarland EJ, Kuritzkes DRCurrent clinical topics in infectious diseasesClinical features and treatment of infection due to mycobacterium fortuitum/chelonae complex. Curr Clin Top Infect Dis. 1993; 13:188-202.Curr Clin Top Infect Dis1993-01-01T00:00:001993Clinical features and treatment of infection due to mycobacterium fortuitum/chelonae complex.19019971Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DRJournal of virologyIn vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol. 2009 Feb; 83(4):2038-43.J Virol2008-11-19T00:00:002008In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.19191652Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, Hughes MD, Aberg JA, Currier JS, Tashima K, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin TJ, Gulick RM, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaLymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis. 2009 Mar 01; 48(5):642-9.Clin Infect Dis2009-03-01T00:00:002009Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.20550776Murphy RA, Sunpath H, Taha B, Kappagoda S, Maphasa KT, Kuritzkes DR, Smeaton LThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung DiseaseLow uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010 Jul; 14(7):903-8.Int J Tuberc Lung Dis2010-07-01T00:00:002010Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa.21467286Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DRJAMALow-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011 Apr 06; 305(13):1327-35.JAMA2011-04-06T00:00:002011Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.21849432Hu Z, Kuritzkes DRJournal of virologyInteraction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol. 2011 Nov; 85(21):11309-14.J Virol2011-08-17T00:00:002011Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.22180526Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti AHIV clinical trialsPharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials. 2011 Sep-Oct; 12(5):277-85.HIV Clin Trials2011-09-01T00:00:002011Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.22427821Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, Freedberg KA, Wood RPloS oneVirologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012; 7(3):e32144.PLoS One2012-03-13T00:00:002012Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.Microbiology10983642Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CBAIDS (London, England)Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. AIDS. 2000 Jul 28; 14(11):1553-61.AIDS2000-07-28T00:00:002000Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.11023459Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich MThe Journal of infectious diseasesTwo double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000 Nov; 182(5):1357-64.J Infect Dis2000-10-09T00:00:002000Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.Authorship 115979311679926Duan C, Poticha D, Stoeckli TC, Petropoulos CJ, Whitcomb JM, McHenry CS, Kuritzkes DRThe Journal of infectious diseasesInhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates. J Infect Dis. 2001 Nov 15; 184(10):1336-40.J Infect Dis2001-10-15T00:00:002001Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.14595419Kuritzkes D, Lange J, Zewdie DNature medicineWorld Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries. Nat Med. 2003 Nov; 9(11):1343-4.Nat Med2003-11-01T00:00:002003World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries.14600574Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RBJournal of acquired immune deficiency syndromes (1999)MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003 Nov 01; 34(3):295-8.J Acquir Immune Defic Syndr2003-11-01T00:00:002003MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.14657759Tenorio AR, Smith KY, Kuritzkes DR, Sha BE, Donoval B, Young R, Jennings C, Bremer J, Shott S, Landay A, Kessler HAJournal of acquired immune deficiency syndromes (1999)HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.J Acquir Immune Defic Syndr2003-12-15T00:00:002003HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.15980686Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JGJournal of acquired immune deficiency syndromes (1999)Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr. 2005 Jul 01; 39(3):272-83.J Acquir Immune Defic Syndr2005-07-01T00:00:002005Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance.17668562Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP, Landay A, Bastow B, Haas DW, Tashima KT, Jain MK, Deeks SG, Bartlett JAAntiviral therapyA randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.Antivir Ther2007-01-01T00:00:002007A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.20102271Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DRThe Journal of infectious diseasesPre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010 Mar; 201(5):662-71.J Infect Dis2010-03-01T00:00:002010Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.21051598Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC, Olender SA, Ostrowski M, Owen WF, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao MScience (New York, N.Y.)The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7.Science2010-11-04T00:00:002010The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.21709569Singh A, Sunpath H, Green TN, Padayachi N, Hiramen K, Lie Y, Anton ED, Murphy R, Reeves JD, Kuritzkes DR, Ndung'u TJournal of acquired immune deficiency syndromes (1999)Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):233-40.J Acquir Immune Defic Syndr2011-11-01T00:00:002011Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options.22890763Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano HAntimicrobial agents and chemotherapyPrevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012 Nov; 56(11):5998-6000.Antimicrob Agents Chemother2012-08-13T00:00:002012Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.7687641Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DRThe Journal of infectious diseasesInhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. J Infect Dis. 1993 Aug; 168(2):318-26.J Infect Dis1993-08-01T00:00:001993Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.10608789Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, Sevin AD, Fox L, Chiozzi MH, Leonard JM, Rousseau F, D'Arc Roe J, Martinez A, Kessler H, Landay AThe Journal of infectious diseasesImmune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000 Jan; 181(1):358-63.J Infect Dis2000-01-01T00:00:002000Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.12402803Kuritzkes DThe AIDS readerDrug resistance. Navigating resistance pathways. AIDS Read. 2002 Sep; 12(9):395-400, 407.AIDS Read2002-09-01T00:00:002002Drug resistance. Navigating resistance pathways.14583845Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF, Sutcliffe C, Siminski S, Andersen J, Coughlin K, Clayton EW, Haines J, Marshak A, Saag M, Lawrence J, Gustavson J, Anne Bennett J, Christensen R, Matula MA, Wood AJHIV clinical trialsA multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials. 2003 Sep-Oct; 4(5):287-300.HIV Clin Trials2003-09-01T00:00:002003A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.14976591Kuritzkes DRThe Journal of infectious diseasesEthical conduct of research in resource-limited settings. J Infect Dis. 2004 Mar 01; 189(5):764-5.J Infect Dis2004-02-17T00:00:002004Ethical conduct of research in resource-limited settings.15078945Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DRJournal of virologyRelative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol. 2004 May; 78(9):4628-37.J Virol2004-05-01T00:00:002004Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).16885776Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr. 2006 Sep; 43(1):60-4.J Acquir Immune Defic Syndr2006-09-01T00:00:002006Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.17711378Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MPAIDS patient care and STDsTORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS. 2007 Aug; 21(8):533-43.AIDS Patient Care STDS2007-08-01T00:00:002007TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.18090299Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, van Widenfelt E, Musonda R, Novitsky V, Gaolathe T, Ndwapi N, Essex M, Kuritzkes DR, DeGruttola V, Marlink RGJournal of acquired immune deficiency syndromes (1999)Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr. 2007 Nov 01; 46(3):318-22.J Acquir Immune Defic Syndr2007-11-01T00:00:002007Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.18193496Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RMJournal of acquired immune deficiency syndromes (1999)Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007 Dec 15; 46(5):547-54.J Acquir Immune Defic Syndr2007-12-15T00:00:002007Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.19856548Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med. 2008 Aug-Sep; 16(3):266-85.Top HIV Med2008-08-01T00:00:002008Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.22732468Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption. J Acquir Immune Defic Syndr. 2012 Sep 01; 61(1):19-22.J Acquir Immune Defic Syndr2012-09-01T00:00:002012Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption.Authorship 108824178680885Kessler HA, Hurwitz S, Farthing C, Benson CA, Feinberg J, Kuritzkes DR, Bailey TC, Safrin S, Steigbigel RT, Cheeseman SH, McKinley GF, Wettlaufer B, Owens S, Nevin T, Korvick JAJournal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology AssociationPilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 01; 12(2):147-52.J Acquir Immune Defic Syndr Hum Retrovirol1996-06-01T00:00:001996Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group.Authorship 1130599530503325Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy AThe lancet. HIVRisks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV. 2019 Feb; 6(2):e116-e127.Lancet HIV2018-11-29T00:00:002018Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.Authorship 116111Authorship 1277617Authorship 11200230885693Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BDThe lancet. HIVRecommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. Lancet HIV. 2019 04; 6(4):e259-e268.Lancet HIV2019-03-15T00:00:002019Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.D015497Living Beings83469310.277707HIV-1Authorship 114097619D024882Physiology2078290.669001Drug Resistance, ViralAuthorship 1212805D015658Disorders1931167640.15209HIV InfectionsD019380Chemicals & Drugs64943200.317603Anti-HIV AgentsAuthorship 11496041531045650Asundi A, Robles Y, Starr T, Landay A, Kinslow J, Ladner J, White L, Plank RM, Melbourne K, Weisholtz D, Bennett M, Pan H, Stern E, Lin A, Kuritzkes DR, Lin NHJournal of acquired immune deficiency syndromes (1999)Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor. J Acquir Immune Defic Syndr. 2019 08 15; 81(5):585-593.J Acquir Immune Defic Syndr2019-08-15T00:00:002019Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor.D018894Chemicals & Drugs1836240.748789Reverse Transcriptase InhibitorsCenter for Biostatistics in AIDS ResearchImmunology and Infectious DiseasesMedicineGeneral Internal MedicineInfectious DiseaseBeth Israel Deaconess Medical CenterBrigham and Women's HospitalDana-Farber Cancer InstituteHarvard T.H. Chan School of Public HealthMassachusetts General HospitalKHM2KennethMayerKenneth Hugh Mayer, M.D.42.34652700000000-71.0878720000000068578Mayer, KennethProfessor of MedicinePES2PaulSaxPaul Edward Sax, M.D.42.33510370000000-71.1061649000000067048Sax, PaulProfessor of MedicineAuthorship 11569731531131858Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PEClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAntiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020 04 10; 70(8):1636-1642.Clin Infect Dis2020-04-10T00:00:002020Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.BDW1BruceWalkerBruce David Walker, M.D.42.37730000000000-71.0525000000000079342Walker, BrucePhillip T. and Susan M. Ragon Professor of MedicineJH198JessicaHabererJessica Haberer, M.D.42.37283520000000-71.1212038000000077031Haberer, JessicaProfessor of MedicineJZL2JonathanLiJonathan Zheng Li, M.D.42.36070000000000-71.1009000000000058291Li, JonathanAssociate Professor of MedicineMSH1MartinHirschMartin Stanley Hirsch, M.D.42.36070000000000-71.1009000000000023200Hirsch, MartinProfessor of MedicineRLS1RogerShapiroRoger Shapiro, M.D.42.33700000000000-71.1100000000000044651Shapiro, RogerProfessor of Immunology and Infectious DiseasesAT39AtheTsibrisAthe Michael Noel Tsibris, M.D.42.36241700000000-71.0689370000000049336Tsibris, AtheAssociate Professor of MedicineJGS10JosephSodroskiJoseph Gerard Sodroski, M.D.42.33789600000000-71.1072493000000042351Sodroski, JosephProfessor of MicrobiologyAuthorship 1160462731191914Murray BR, Kratka A, Scherr KA, Eyal N, Blumenthal-Barby J, Freedberg KA, Kuritzkes DR, Hammitt JK, Edifor R, Katz MN, Pollak KI, Zikmund-Fisher BJ, Halpern SD, Barks MC, Ubel PAJournal of virus eradicationWhat risk of death would people take to be cured of HIV and why? A survey of people living with HIV. J Virus Erad. 2019 Apr 01; 5(2):109-115.J Virus Erad2019-04-01T00:00:002019What risk of death would people take to be cured of HIV and why? A survey of people living with HIV.MBG3MarciaGoldbergMarcia Beurman Goldberg, M.D.42.36070000000000-71.100900000000005932Goldberg, MarciaProfessor of MedicineAuthorship 1340952HJR1HeatherRibaudoHeather Jane Ribaudo, Ph.D.42.33547570000000-71.1014834000000049886Ribaudo, HeatherPrincipal Research ScientistZH9ZixinHuZixin Hu, Ph.D.42.36070000000000-71.100900000000005328Hu, ZixinResearch Associate in Medicine11425selected publications13.17890.00185345799research areas6.53960.00506416137coauthor of725.78959.984160similar toBE16BehzadEtemadBehzad Etemad, Ph.D.42.36070000000000-71.1009000000000017192Etemad, BehzadResearch Associate in MedicineAuthorship 13158712Authorship 1442441Authorship 14480119Authorship 1474234Authorship 1626062Authorship 1648252true1Professor of MicrobiologyProfessor of Microbiologytrue1Research Associate in MedicineResearch Associate in Medicinetrue1Harriet Ryan Albee Professor of MedicineHarriet Ryan Albee Professor of Medicinetrue1Research Associate in MedicineResearch Associate in MedicineAuthorship 12072281Authorship 12093401831774915Kuritzkes DRThe Journal of infectious diseasesNew Perspectives on the Virologic Consequences of M184V or I in Human Immunodeficiency Virus-1 Reverse Transcriptase. J Infect Dis. 2020 09 01; 222(7):1067-1069.J Infect Dis2020-09-01T00:00:002020New Perspectives on the Virologic Consequences of M184V or I in Human Immunodeficiency Virus-1 Reverse Transcriptase.31776292Garcia-Broncano P, Maddali S, Einkauf KB, Jiang C, Gao C, Chevalier J, Chowdhury FZ, Maswabi K, Ajibola G, Moyo S, Mohammed T, Ncube T, Makhema J, Jean-Philippe P, Yu XG, Powis KM, Lockman S, Kuritzkes DR, Shapiro R, Lichterfeld MScience translational medicineEarly antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Sci Transl Med. 2019 11 27; 11(520).Sci Transl Med2019-11-27T00:00:002019Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile.Authorship 13586412Authorship 12149361031900813Fridman I, Ubel PA, Blumenthal-Barby J, England CV, Currier JS, Eyal N, Freedberg KA, Halpern SD, Kelley CF, Kuritzkes DR, Le CN, Lennox JL, Pollak KI, Zikmund-Fisher BJ, Scherr KAAIDS and behavior"Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication. AIDS Behav. 2020 Jul; 24(7):2054-2061.AIDS Behav2020-07-01T00:00:002020"Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication.Authorship 1317151Authorship 12183061331927562Maswabi K, Ajibola G, Bennett K, Capparelli EV, Jean-Philippe P, Moyo S, Mohammed T, Batlang O, Sakoi M, Lockman S, Makhema J, Lichterfeld M, Kuritzkes DR, Hughes MD, Shapiro RLClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaSafety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clin Infect Dis. 2021 02 01; 72(3):388-393.Clin Infect Dis2021-02-01T00:00:002021Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life.23688050Inci F, Tokel O, Wang S, Gurkan UA, Tasoglu S, Kuritzkes DR, Demirci UACS nanoNanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano. 2013 Jun 25; 7(6):4733-45.ACS Nano2013-05-20T00:00:002013Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood.23447456Shafiee H, Jahangir M, Inci F, Wang S, Willenbrecht RB, Giguel FF, Tsibris AM, Kuritzkes DR, Demirci USmall (Weinheim an der Bergstrasse, Germany)Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small. 2013 Aug 12; 9(15):2553-63, 2478.Small2013-02-27T00:00:002013Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate.Authorship 1227595632035041Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio SThe lancet. HIVUpdated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV. 2020 03; 7(3):e193-e200.Lancet HIV2020-02-05T00:00:002020Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.Authorship 123171314Authorship 12318721432195745Davey S, Ajibola G, Maswabi K, Sakoi M, Bennett K, Hughes MD, Isaacson A, Diseko M, Zash R, Batlang O, Moyo S, Lockman S, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro RJournal of acquired immune deficiency syndromes (1999)Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana. J Acquir Immune Defic Syndr. 2020 07 01; 84(3):235-241.J Acquir Immune Defic Syndr2020-07-01T00:00:002020Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.32160755Dubé K, Hosey L, Starr K, Barr L, Evans D, Hoffman E, Campbell DM, Simoni J, Sugarman J, Sauceda J, Brown B, Diepstra KL, Godfrey C, Kuritzkes DR, Wohl DA, Gandhi R, Scully EAIDS research and human retrovirusesParticipant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366. AIDS Res Hum Retroviruses. 2020 04; 36(4):268-282.AIDS Res Hum Retroviruses2020-04-01T00:00:002020Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366.Authorship 1808038Authorship 174182432287064Ajibola G, Moyo S, Mohammed T, Moseki S, Jack D, Sakoi M, Batlang O, Maswabi K, Bennett K, Hughes MD, Lockman S, Makhema JM, Lichterfeld M, Kuritzkes DR, Shapiro RLAIDS (London, England)HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life. AIDS. 2020 06 01; 34(7):1029-1035.AIDS2020-06-01T00:00:002020HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life.Authorship 124144614Authorship 12525911032496516Jilg N, Garcia-Broncano P, Peluso M, Segal FP, Bosch RJ, Roberts-Toler C, Chen SMY, Van Dam CN, Keefer MC, Kuritzkes DR, Landay AL, Deeks S, Yu XG, Sax PE, Li JZThe Journal of infectious diseasesMaintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. J Infect Dis. 2020 11 09; 222(11):1837-1842.J Infect Dis2020-11-09T00:00:002020Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy.Authorship 12548771532555469Tomezsko PJ, Corbin VDA, Gupta P, Swaminathan H, Glasgow M, Persad S, Edwards MD, Mcintosh L, Papenfuss AT, Emery A, Swanstrom R, Zang T, Lan TCT, Bieniasz P, Kuritzkes DR, Tsibris A, Rouskin SNatureDetermination of RNA structural diversity and its role in HIV-1 RNA splicing. Nature. 2020 06; 582(7812):438-442.Nature2020-05-06T00:00:002020Determination of RNA structural diversity and its role in HIV-1 RNA splicing.Authorship 1356017Authorship 1367076Authorship 1451704Authorship 1678509Authorship 1788336Authorship 1364915Authorship 133028133127906Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-Trocha A, Atyeo C, Fischinger S, Chan A, Flaherty KT, Hall K, Dougan M, Ryan ET, Gillespie E, Chishti R, Li Y, Jilg N, Hanidziar D, Baron RM, Baden L, Tsibris AM, Armstrong KA, Kuritzkes DR, Alter G, Walker BD, Yu X, Li JZNature communicationsSARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020 10 30; 11(1):5493.Nat Commun2020-10-30T00:00:002020SARS-CoV-2 viral load is associated with increased disease severity and mortality.Authorship 1429361Authorship 1908001Authorship 1367702Authorship 129980726Authorship 13936411Authorship 1519301Authorship 130358615Authorship 130606510Authorship 13046961433226787Shokr A, Pacheco LGC, Thirumalaraju P, Kanakasabapathy MK, Gandhi J, Kartik D, Silva FSR, Erdogmus E, Kandula H, Luo S, Yu XG, Chung RT, Li JZ, Kuritzkes DR, Shafiee HACS nanoMobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. ACS Nano. 2021 01 26; 15(1):665-673.ACS Nano2020-11-23T00:00:002020Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning.33176715Brijkumar J, Johnson BA, Zhao Y, Edwards J, Moodley P, Pathan K, Pillay S, Castro KG, Sunpath H, Kuritzkes DR, Moosa MYS, Marconi VCBMC infectious diseasesA packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa. BMC Infect Dis. 2020 Nov 11; 20(1):836.BMC Infect Dis2020-11-11T00:00:002020A packaged intervention to improve viral load monitoring within a deeply rural health district of South Africa.33214714Tomezsko PJ, Corbin VDA, Gupta P, Swaminathan H, Glasgow M, Persad S, Edwards MD, Mcintosh L, Papenfuss AT, Emery A, Swanstrom R, Zang T, Lan TCT, Bieniasz P, Kuritzkes DR, Tsibris A, Rouskin SNatureAuthor Correction: Determination of RNA structural diversity and its role in HIV-1 RNA splicing. Nature. 2020 Dec; 588(7837):E16.Nature2020-12-01T00:00:002020Author Correction: Determination of RNA structural diversity and its role in HIV-1 RNA splicing.Authorship 1442052true1Associate Professor of MedicineAssociate Professor of Medicinetrue1Professor of MedicineProfessor of MedicineAuthorship 2443244Authorship 13313961333605999Ajibola G, Garcia-Broncano P, Maswabi K, Bennett K, Hughes MD, Moyo S, Mohammed T, Jean-Philippe P, Sakoi M, Batlang O, Lockman S, Makhema J, Kuritzkes DR, Lichterfeld M, Shapiro RLClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaViral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clin Infect Dis. 2021 08 16; 73(4):e997-e1003.Clin Infect Dis2021-08-16T00:00:002021Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression.33693678Li JZ, Stella N, Choudhary MC, Javed A, Rodriguez K, Ribaudo H, Moosa MY, Brijkumar J, Pillay S, Sunpath H, Noguera-Julian M, Paredes R, Johnson B, Edwards A, Marconi VC, Kuritzkes DRThe Journal of antimicrobial chemotherapyImpact of pre-existing drug resistance on risk of virological failure in South Africa. J Antimicrob Chemother. 2021 05 12; 76(6):1558-1563.J Antimicrob Chemother2021-05-12T00:00:002021Impact of pre-existing drug resistance on risk of virological failure in South Africa.Authorship 133826416Authorship 1340076433730748Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, Polli JW, Dorey D, Wang Y, Wu S, Van Eygen V, Crauwels H, Ford SL, Baker M, Talarico CL, Clair MS, Jeffrey J, White CT, Vanveggel S, Vandermeulen K, Margolis DA, Aboud M, Spreen WR, van Lunzen JAIDS (London, England)Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 2021 07 15; 35(9):1333-1342.AIDS2021-07-15T00:00:002021Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.2026-03-31KURITZKES, DANIEL R.;TSIBRIS, ATHE M.2021-04-08HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapyR01AI157854Co-Principal InvestigatorAuthorship 13516141433929394Gay CL, Bosch RJ, McKhann A, Moseley KF, Wimbish CL, Hendrickx SM, Messer M, Furlong M, Campbell DM, Jennings C, Benson C, Overton ET, Macatangay BJC, Kuritzkes DR, Miller E, Tressler R, Eron JJ, Hardy WDJournal of acquired immune deficiency syndromes (1999)Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV. J Acquir Immune Defic Syndr. 2021 08 15; 87(5):e234-e236.J Acquir Immune Defic Syndr2021-08-15T00:00:002021Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV.Authorship 1352997533952300Gatechompol S, Avihingsanon A, Putcharoen O, Ruxrungtham K, Kuritzkes DRAIDS research and therapyCOVID-19 and HIV infection co-pandemics and their impact: a review of the literature. AIDS Res Ther. 2021 05 05; 18(1):28.AIDS Res Ther2021-05-05T00:00:002021COVID-19 and HIV infection co-pandemics and their impact: a review of the literature.Authorship 1360683134081075Kuritzkes DRJAMABamlanivimab for Prevention of COVID-19. JAMA. 2021 07 06; 326(1):31-32.JAMA2021-07-06T00:00:002021Bamlanivimab for Prevention of COVID-19.Authorship 13621311134112997Kanakasabapathy MK, Thirumalaraju P, Kandula H, Doshi F, Sivakumar AD, Kartik D, Gupta R, Pooniwala R, Branda JA, Tsibris AM, Kuritzkes DR, Petrozza JC, Bormann CL, Shafiee HNature biomedical engineeringAdaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images. Nat Biomed Eng. 2021 06; 5(6):571-585.Nat Biomed Eng2021-06-10T00:00:002021Adaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images.Authorship 1724487Authorship 1372837634235860Ferreira FA, He Q, Banning S, Roberts-Sano O, Wilkins O, Kuritzkes DR, Tsibris AJournal of the International AIDS SocietyHIV-1 proviral landscape characterization varies by pipeline analysis. J Int AIDS Soc. 2021 07; 24(7):e25725.J Int AIDS Soc2021-07-01T00:00:002021HIV-1 proviral landscape characterization varies by pipeline analysis.Authorship 13791011234324451Moraka NO, Garcia-Broncano P, Hu Z, Ajibola G, Bareng OT, Pretorius-Holme M, Maswabi K, Maphorisa C, Mohammed T, Gaseitsiwe S, VanZyl GU, Kuritzkes DR, Lichterfeld M, Moyo S, Shapiro RLAIDS (London, England)Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. AIDS. 2021 12 01; 35(15):2413-2421.AIDS2021-12-01T00:00:002021Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana.34430669Regan J, Flynn JP, Rosenthal A, Jordan H, Li Y, Chishti R, Giguel F, Corry H, Coxen K, Fajnzylber J, Gillespie E, Kuritzkes DR, Hacohen N, Goldberg MB, Filbin MR, Yu XG, Baden L, Ribeiro RM, Perelson AS, Conway JM, Li JZOpen forum infectious diseasesViral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infect Dis. 2021 Aug; 8(8):ofab153.Open Forum Infect Dis2021-04-17T00:00:002021Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019.Authorship 138915012Authorship 13935861034514084Silva FSR, Erdogmus E, Shokr A, Kandula H, Thirumalaraju P, Kanakasabapathy MK, Hardie JM, Pacheco LGC, Li JZ, Kuritzkes DR, Shafiee HAdvanced materials technologiesSARS-CoV-2 RNA Detection by a Cellphone-Based Amplification-Free System with CRISPR/CAS-Dependent Enzymatic (CASCADE) Assay. Adv Mater Technol. 2021 Dec; 6(12):2100602.Adv Mater Technol2021-07-19T00:00:002021SARS-CoV-2 RNA Detection by a Cellphone-Based Amplification-Free System with CRISPR/CAS-Dependent Enzymatic (CASCADE) Assay.true1Professor of MedicineProfessor of MedicineAuthorship 1885241Authorship 1398853734596223Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich RClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaRemdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clin Infect Dis. 2022 08 24; 75(1):e450-e458.Clin Infect Dis2022-08-24T00:00:002022Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.Authorship 188041Authorship 1921013Authorship 141900612Authorship 1419593234930466Matoori S, Kuritzkes DR, Goh Y, Quek ST, Wang L, Sun Z, di Marco F, Borleri D, Buoro S, Fagiuoli S, Ferrari T, Rizzi M, Raimondi F, Cesa S, Koh DM, Froehlich JM, Janssen S, Lange B, Egle A, Erb S, Mossdorf E, Gutzeit AAntimicrobial resistance and infection controlPreparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19. Antimicrob Resist Infect Control. 2021 12 20; 10(1):170.Antimicrob Resist Infect Control2021-12-20T00:00:002021Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19.34910844Castillo-Mancilla JR, Edwards JA, Brijkumar J, Moosa MY, Zhao Y, Ofotokun I, Johnson BA, Lee MH, Pillay S, Pillay M, Moodley P, Kuritzkes DR, Sunpath H, Bushman LR, Ellison L, Anderson PL, Marconi VCJournal of the International AIDS SocietyTenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. J Int AIDS Soc. 2021 12; 24(12):e25849.J Int AIDS Soc2021-12-01T00:00:002021Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study.Authorship 1422634834984212Mozaffari E, Chandak A, Zhang Z, Liang S, Gayle J, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich ROpen forum infectious diseasesClinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. Open Forum Infect Dis. 2022 Jan; 9(1):ofab498.Open Forum Infect Dis2021-09-28T00:00:002021Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States.Authorship 165141135023287Brijkumar J, Edwards JA, Johnson BA, Ordonez C, Sunpath H, Lee M, Dudgeon MR, Rautman L, Pillay S, Moodley P, Sun YV, Castillo-Mancilla J, Li JZ, Kuritzkes DR, Moosa MYS, Marconi VCHIV medicineComparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa. HIV Med. 2022 08; 23(7):727-737.HIV Med2022-01-12T00:00:002022Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.Authorship 142464814Authorship 2078715Authorship 2111712Authorship 2190905Authorship 231563Authorship 14303351135097250Lederman MM, Flier JS, Hale P, Haase AT, Powderly W, Reiss P, Silvestri G, Sekaly RP, Paiardini M, Weissman D, Kuritzkes DR, Calabrese LH, Agre P, Reyes-Teran G, Landay AL, Lewin S, Richman DD, Volberding P, Hunt PW, Schechter MPathogens & immunityIs France Once Again Looking for a Scapegoat? Pathog Immun. 2021; 6(2):149-152.Pathog Immun2021-12-29T00:00:002021Is France Once Again Looking for a Scapegoat?Authorship 14369726Authorship 144125023Authorship 1441342235176755Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, Morse GD, Squires KE, Howell BJ, Wu G, Hosey L, Sieg SF, Ehui L, Giguel F, Coxen K, Dobrowolski C, Gandhi M, Deeks S, Chomont N, Connick E, Godfrey C, Karn J, Kuritzkes DR, Bosch RJ, Gandhi RTClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaImpact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis. 2022 10 12; 75(8):1389-1396.Clin Infect Dis2022-10-12T00:00:002022Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.35226530Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back D, Khoo SAnnals of internal medicinePrescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. Ann Intern Med. 2022 05; 175(5):744-746.Ann Intern Med2022-03-01T00:00:002022Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.35293094Orkin C, Cahn P, Castagna A, Emu B, Harrigan PR, Kuritzkes DR, Nelson M, Schapiro JHIV medicineOpening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV. HIV Med. 2022 10; 23(9):936-946.HIV Med2022-03-16T00:00:002022Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV.Authorship 1450943235567754Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo SClinical pharmacology and therapeuticsRecommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther. 2022 12; 112(6):1191-1200.Clin Pharmacol Ther2022-06-07T00:00:002022Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.Authorship 3443841Authorship 146000313Authorship 14595852435888748Liu C, Wang Z, Hui Q, Chiang Y, Chen J, Brijkumar J, Edwards JA, Ordonez CE, Dudgeon MR, Sunpath H, Pillay S, Moodley P, Kuritzkes DR, Moosa MYS, Jones DP, Marconi VC, Sun YVMetabolitesCrosstalk between Host Genome and Metabolome among People with HIV in South Africa. Metabolites. 2022 Jul 06; 12(7).Metabolites2022-07-06T00:00:002022Crosstalk between Host Genome and Metabolome among People with HIV in South Africa.35858580Hartana CA, Garcia-Broncano P, Rassadkina Y, Lian X, Jiang C, Einkauf KB, Maswabi K, Ajibola G, Moyo S, Mohammed T, Maphorisa C, Makhema J, Yuki Y, Martin M, Bennett K, Jean-Philippe P, Viard M, Hughes MD, Powis KM, Carrington M, Lockman S, Gao C, Yu XG, Kuritzkes DR, Shapiro R, Lichterfeld MCell reportsImmune correlates of HIV-1 reservoir cell decline in early-treated infants. Cell Rep. 2022 07 19; 40(3):111126.Cell Rep2022-07-19T00:00:002022Immune correlates of HIV-1 reservoir cell decline in early-treated infants.Authorship 40416218Authorship 42687212Authorship 4324283Authorship 4332751Authorship 15013041Authorship 148060223Authorship 1483061236106155Magalhaes M, Kuritzkes DR, Eyal NJournal of virus eradicationThe ethical case for placebo control in HIV-cure-related studies with ART interruption. J Virus Erad. 2022 Sep; 8(3):100084.J Virus Erad2022-08-28T00:00:002022The ethical case for placebo control in HIV-cure-related studies with ART interruption.36354048Kuritzkes DRThe lancet. HIVApproaching the asymptote. Lancet HIV. 2023 01; 10(1):e5-e7.Lancet HIV2022-10-27T00:00:002022Approaching the asymptote.36094485Capparelli EV, Ajibola G, Maswabi K, Holme MP, Bennett K, Powis KM, Moyo S, Mohammed T, Maphorisa C, Hughes MD, Seaton KE, Tomaras GD, Mosher S, Taylor A, O'Connell S, Narpala S, Mcdermott A, Caskey M, Gama L, Lockman S, Jean-Philippe P, Makhema J, Kuritzkes DR, Lichterfeld M, Shapiro RLJournal of acquired immune deficiency syndromes (1999)Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):182-188.J Acquir Immune Defic Syndr2022-10-01T00:00:002022Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children.Authorship 1506303236410387Caskey M, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaMonoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)? Clin Infect Dis. 2022 11 21; 75(Suppl 4):S530-S540.Clin Infect Dis2022-11-21T00:00:002022Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?Authorship 194276Authorship 2011051Authorship 15163192Authorship 15157601436660823Llibre JM, Kuritzkes DARClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaLong-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities. Clin Infect Dis. 2023 05 03; 76(9):1655-1657.Clin Infect Dis2023-05-03T00:00:002023Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities.36642087Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, Kripke K, Revill P, Boily MC, Meyer-Rath G, Taramusi I, Lundgren JD, van Oosterhout JJ, Kuritzkes D, Schaefer R, Siedner MJ, Schapiro J, Delany-Moretlwe S, Landovitz RJ, Flexner C, Jordan M, Venter F, Radebe M, Ripin D, Jenkins S, Resar D, Amole C, Shahmanesh M, Gupta RK, Raizes E, Johnson C, Inzaule S, Shafer R, Warren M, Stansfield S, Paredes R, Phillips ANThe lancet. HIVPredicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 04; 10(4):e254-e265.Lancet HIV2023-01-12T00:00:002023Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.Authorship 2258366Authorship 15217801536729692Ajibola G, Maswabi K, Hughes MD, Bennett K, Pretorius-Holme M, Capparelli EV, Jean-Philippe P, Moyo S, Mohammed T, Batlang O, Sakoi M, Ricci L, Lockman S, Makhema J, Kuritzkes DR, Lichterfeld M, Shapiro RLJournal of acquired immune deficiency syndromes (1999)Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial. J Acquir Immune Defic Syndr. 2023 04 15; 92(5):393-398.J Acquir Immune Defic Syndr2023-04-15T00:00:002023Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.Authorship 1807995Authorship 15305811036911658Archin N, Bar KJ, Burdo T, Caskey M, Chahroudi A, Farzan M, Ho YC, Jones RB, Kearney M, Kuritzkes D, Margolis D, Martinez-Picado J, Okoye A, Salgado M, Stevenson MJournal of virus eradicationHighlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA. J Virus Erad. 2023 Mar; 9(1):100315.J Virus Erad2023-01-27T00:00:002023Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA.Authorship 1932566Authorship 485588Ragon Institute of MGH, MIT and HarvardAuthorship 156806931Authorship 15635054Authorship 15514371Authorship 156963615Authorship 15608316Authorship 156356928Authorship 15580984Authorship 15646551437497681Hu Z, Cordwell T, Nguyen H, Li J, Jeffrey JL, Kuritzkes DRThe Journal of infectious diseasesEffect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6. J Infect Dis. 2023 11 11; 228(10):1352-1356.J Infect Dis2023-11-11T00:00:002023Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6.37265259Kuritzkes DRCurrent opinion in HIV and AIDSBroadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV. Curr Opin HIV AIDS. 2023 07 01; 18(4):225-228.Curr Opin HIV AIDS2023-05-09T00:00:002023Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV.37034605Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZmedRxiv : the preprint server for health sciencesViral and Host Mediators of Non-Suppressible HIV-1 Viremia. medRxiv. 2023 Mar 31.medRxiv2023-03-31T00:00:002023Viral and Host Mediators of Non-Suppressible HIV-1 Viremia.37406137Shapiro RL, Ajibola G, Maswabi K, Hughes M, Nelson BS, Niesar A, Pretorius Holme M, Powis KM, Sakoi M, Batlang O, Moyo S, Mohammed T, Maphorisa C, Bennett K, Hu Z, Giguel F, Reeves JD, Reeves MA, Gao C, Yu X, Ackerman ME, McDermott A, Cooper M, Caskey M, Gama L, Jean-Philippe P, Yin DE, Capparelli EV, Lockman S, Makhema J, Kuritzkes DR, Lichterfeld MScience translational medicineBroadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Sci Transl Med. 2023 07 05; 15(703):eadh0004.Sci Transl Med2023-07-05T00:00:002023Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.37469618Hirsh ML, Edwards JA, Robichaux C, Brijkumar J, Moosa MS, Ofotokun I, Johnson BA, Pillay S, Pillay M, Moodley P, Sun YV, Liu C, Dudgeon MR, Ordoñez C, Kuritzkes DR, Sunpath H, Morrow M, Anderson PL, Ellison L, Bushman LR, Marconi VC, Castillo-Mancilla JROpen forum infectious diseasesFood Insecurity Is Associated With Low Tenofovir Diphosphate in Dried Blood Spots in South African Persons With HIV. Open Forum Infect Dis. 2023 Jul; 10(7):ofad360.Open Forum Infect Dis2023-07-13T00:00:002023Food Insecurity Is Associated With Low Tenofovir Diphosphate in Dried Blood Spots in South African Persons With HIV.37201510Hartana CA, Broncano PG, Maswabi K, Ajibola G, Moyo S, Mohammed T, Maphorisa C, Makhema J, Powis KM, Lockman S, Burbelo PD, Gao C, Yu XG, Kuritzkes DR, Shapiro R, Lichterfeld MThe Journal of infectious diseasesImmune Modulation of HIV-1 Reservoir Size in Early-Treated Neonates. J Infect Dis. 2023 08 11; 228(3):281-286.J Infect Dis2023-08-11T00:00:002023Immune Modulation of HIV-1 Reservoir Size in Early-Treated Neonates.37340869Orkin C, Schapiro JM, Perno CF, Kuritzkes DR, Patel P, DeMoor R, Dorey D, Wang Y, Han K, Van Eygen V, Crauwels H, Ford SL, Latham CL, St Clair M, Polli JW, Vanveggel S, Vandermeulen K, D'Amico R, Garges HP, Zolopa A, Spreen WR, van Wyk J, Cutrell AGClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaExpanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure. Clin Infect Dis. 2023 11 17; 77(10):1423-1431.Clin Infect Dis2023-11-17T00:00:002023Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.37139652Slama L, Hardy WD, Quiñones-Mateu ME, Kuritzkes DRAIDS (London, England)Alternative options for treatment-experienced people with HIV. AIDS. 2023 06 01; 37(7):1165-1166.AIDS2023-06-01T00:00:002023Alternative options for treatment-experienced people with HIV.Authorship 2950956Authorship 3321041Authorship 159178411Authorship 15896002237672793Chen J, Hui Q, Liu C, Brijkumar J, Edwards JA, Ordóñez CE, Dudgeon MR, Sunpath H, Pillay S, Moodley P, Kuritzkes DR, Moosa MYS, Nemoto T, Marconi VC, Sun YVProteomics. Clinical applicationsAssociations of inflammation-related proteome with demographic and clinical characteristics of people with HIV in South Africa. Proteomics Clin Appl. 2024 Jan; 18(1):e2300015.Proteomics Clin Appl2023-09-06T00:00:002023Associations of inflammation-related proteome with demographic and clinical characteristics of people with HIV in South Africa.37738247Inzaule SC, Siedner MJ, Little SJ, Avila-Rios S, Ayitewala A, Bosch RJ, Calvez V, Ceccherini-Silberstein F, Charpentier C, Descamps D, Eshleman SH, Fokam J, Frenkel LM, Gupta RK, Ioannidis JPA, Kaleebu P, Kantor R, Kassaye SG, Kosakovsky Pond SL, Kouamou V, Kouyos RD, Kuritzkes DR, Lessells R, Marcelin AG, Mbuagbaw L, Minalga B, Ndembi N, Neher RA, Paredes R, Pillay D, Raizes EG, Rhee SY, Richman DD, Ruxrungtham K, Sabeti PC, Schapiro JM, Sirivichayakul S, Steegen K, Sugiura W, van Zyl GU, Vandamme AM, Wensing AMJ, Wertheim JO, Gunthard HF, Jordan MR, Shafer RWPLoS medicineRecommendations on data sharing in HIV drug resistance research. PLoS Med. 2023 Sep; 20(9):e1004293.PLoS Med2023-09-22T00:00:002023Recommendations on data sharing in HIV drug resistance research.Authorship 3817854Authorship 40587515true1Phillip T. and Susan M. Ragon Professor of MedicinePhillip T. and Susan M. Ragon Professor of MedicineAuthorship 45379710Authorship 4692562Authorship 4829709Authorship 16095019Authorship 16092622Authorship 160996131Authorship 1609248737957382Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Crain CR, Traunbauer AK, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Dorazio D, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Sieg S, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZNature medicineViral and host mediators of non-suppressible HIV-1 viremia. Nat Med. 2023 Dec; 29(12):3212-3223.Nat Med2023-11-13T00:00:002023Viral and host mediators of non-suppressible HIV-1 viremia.38051788Jacobson JM, Felber BK, Chen H, Pavlakis GN, Mullins JI, de Rosa SC, Kuritzkes DR, Tomaras GD, Kinslow J, Bao Y, Olefsky M, Rosati M, Bear J, Hannaman D, Laird GM, Cyktor JC, Heath SL, Collier AC, Koletar SL, Taiwo BO, Tebas P, Wohl DA, Belanzauran-Zamudio PF, Mcelrath MJ, Landay ALAIDS (London, England)The immunogenicity of an HIV-1 gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy. AIDS. 2023 Dec 04.AIDS2023-12-04T00:00:002023The immunogenicity of an HIV-1 gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy.38051993Horga A, Kuritzkes DR, Kowalczyk JJ, Pietropaolo K, Belanger B, Lin K, Perkins K, Hammond JFuture virologyPhase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19. Future Virol. 2023 Jun; 18(8):489-500.Future Virol2023-06-23T00:00:002023Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19.37949070Sponaugle A, Weideman AMK, Ranek J, Atassi G, Kuruc J, Adimora AA, Archin NM, Gay C, Kuritzkes DR, Margolis DM, Vincent BG, Stanley N, Hudgens MG, Eron JJ, Goonetilleke NCell reports. MedicineDominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. Cell Rep Med. 2023 11 21; 4(11):101268.Cell Rep Med2023-11-09T00:00:002023Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV.Authorship 4987046Authorship 51814742028-06-30SHAPIRO, ROGER L2023-09-05A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in BotswanaU01AI179561Co-Principal InvestigatorAuthorship 1703827Authorship 16318802038367616Armani-Tourret M, Gao C, Hartana CA, Sun W, Carrere L, Vela L, Hochroth A, Bellefroid M, Sbrolla A, Shea K, Flynn T, Roseto I, Rassadkina Y, Lee C, Giguel F, Malhotra R, Bushman FD, Gandhi RT, Yu XG, Kuritzkes DR, Lichterfeld MCellSelection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-a2a. Cell. 2024 Feb 29; 187(5):1238-1254.e14.Cell2024-02-17T00:00:002024Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-a2a.Authorship 2205671Authorship 16347591838449916Gay CL, Bosch RJ, McKhann A, Cha R, Morse GD, Wimbish CL, Campbell DM, Moseley KF, Hendrickx S, Messer M, Benson CA, Overton ET, Paccaly A, Jankovic V, Miller E, Tressler R, Li JZ, Kuritzkes DR, Macatangay BJC, Eron JJ, Hardy WDOpen forum infectious diseasesSafety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy. Open Forum Infect Dis. 2024 Mar; 11(3):ofad694.Open Forum Infect Dis2024-01-11T00:00:002024Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.Authorship 5223061true1Associate Professor of MedicineAssociate Professor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Professor of Immunology and Infectious DiseasesProfessor of Immunology and Infectious Diseasestrue1Principal Research ScientistPrincipal Research Scientisttrue1Professor of MedicineProfessor of Medicinetrue1Professor of MedicineProfessor of MedicineAuthorship 1550810Authorship 2436607Authorship 2511658Authorship 2672142Authorship 2701172Authorship 3070361Authorship 32491910Authorship 3397975Authorship 3422491Authorship 3580593Authorship 3632057Authorship 3645071Authorship 3862861Authorship 39935010Authorship 4044835Authorship 3148992Authorship 6431012Authorship 6496176Authorship 66711816Authorship 6650058Authorship 659409823599363Taiwo B, Matining RM, Zheng L, Lederman MM, Rinaldo CR, Kim PS, Berzins BI, Kuritzkes DR, Jennings A, Eron JJ, Wilson CCThe Journal of antimicrobial chemotherapyAssociations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. J Antimicrob Chemother. 2013 Aug; 68(8):1857-61.J Antimicrob Chemother2013-04-18T00:00:002013Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.Authorship 3654105Authorship 1888223Authorship 962063Authorship 5671312Authorship 23528013Authorship 6737605Authorship 6757551323303240Orrell C, Levison J, Ciaranello A, Bekker LG, Kuritzkes DR, Freedberg KA, Wood RThe Pediatric infectious disease journalResistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy. Pediatr Infect Dis J. 2013 Jun; 32(6):644-7.Pediatr Infect Dis J2013-06-01T00:00:002013Resistance in pediatric patients experiencing virologic failure with first-line and second-line antiretroviral therapy.23801609Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DRThe Journal of infectious diseasesThree distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013 Sep; 208(6):884-91.J Infect Dis2013-06-24T00:00:002013Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.Authorship 2008051Authorship 679565923797691Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells SJournal of acquired immune deficiency syndromes (1999)Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):167-73.J Acquir Immune Defic Syndr2013-10-01T00:00:002013Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.Authorship 2190882Authorship 2813276Authorship 689057324009230Zou S, Glynn S, Kuritzkes D, Shah M, Cook N, Berliner NBloodHematopoietic cell transplantation and HIV cure: where we are and what next? Blood. 2013 Oct 31; 122(18):3111-5.Blood2013-09-05T00:00:002013Hematopoietic cell transplantation and HIV cure: where we are and what next?Authorship 3183097Authorship 32881110Authorship 692184224182529Eyal N, Kuritzkes DRLancet (London, England)Challenges in clinical trial design for HIV-1 cure research. Lancet. 2013 Nov 02; 382(9903):1464-5.Lancet2013-11-02T00:00:002013Challenges in clinical trial design for HIV-1 cure research.Authorship 3728621Authorship 6977741224320011Marconi VC, Wu B, Hampton J, Ordóñez CE, Johnson BA, Singh D, John S, Gordon M, Hare A, Murphy R, Nachega J, Kuritzkes DR, del Rio C, Sunpath HAIDS patient care and STDsEarly warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic. AIDS Patient Care STDS. 2013 Dec; 27(12):657-68.AIDS Patient Care STDS2013-12-01T00:00:002013Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.24361679Li JZ, Gallien S, Ribaudo H, Heisey A, Bangsberg DR, Kuritzkes DRAIDS (London, England)Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014 Jan 14; 28(2):181-186.AIDS2014-01-14T00:00:002014Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.Authorship 1949705Authorship 6995931224367599Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, Pilch-Cooper HA, Rodriguez B, Feinberg J, Daar E, Mellors J, Kuritzkes D, Jacobson JM, Lederman MMPloS oneDynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One. 2013; 8(12):e83514.PLoS One2013-12-18T00:00:002013Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.Authorship 2515807Authorship 70453810Authorship 704582624448112Wang S, Tasoglu S, Chen PZ, Chen M, Akbas R, Wach S, Ozdemir CI, Gurkan UA, Giguel FF, Kuritzkes DR, Demirci UScientific reportsMicro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care. Sci Rep. 2014 Jan 22; 4:3796.Sci Rep2014-01-22T00:00:002014Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care.Authorship 2431208Authorship 274228Authorship 39329057Authorship 2712541Authorship 2712373Authorship 3039443Authorship 4243524Authorship 2816689Authorship 2844901Authorship 264475Authorship 71959214Authorship 723030724576941Shafiee H, Lidstone EA, Jahangir M, Inci F, Hanhauser E, Henrich TJ, Kuritzkes DR, Cunningham BT, Demirci UScientific reportsNanostructured optical photonic crystal biosensor for HIV viral load measurement. Sci Rep. 2014 Feb 28; 4:4116.Sci Rep2014-02-28T00:00:002014Nanostructured optical photonic crystal biosensor for HIV viral load measurement.24603872Li JZ, Chapman B, Charlebois P, Hofmann O, Weiner B, Porter AJ, Samuel R, Vardhanabhuti S, Zheng L, Eron J, Taiwo B, Zody MC, Henn MR, Kuritzkes DR, Hide W, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Read SW, Janik J, Meres DS, Lederman MM, Mong-Kryspin L, Shaw KE, Zimmerman LG, Leavitt R, De La Rosa G, Jennings APloS oneComparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One. 2014; 9(3):e90485.PLoS One2014-03-06T00:00:002014Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.Authorship 2207056Authorship 3276645Authorship 2413715Authorship 2849904Authorship 990158Authorship 3012181Authorship 2291241Authorship 174127Authorship 3672192Authorship 1878164Authorship 7331881124896805Al-Hajjar SH, Frayha HH, Al-Hazmi M, Batawi R, McIntosh K, Sax PE, Al-Thawadi S, Al-Jumaah S, Busch MP, Hanhauser E, Kuritzkes DR, Li JZ, Henrich TJAIDS (London, England)Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion. AIDS. 2014 Jun 19; 28(10):1539-41.AIDS2014-06-19T00:00:002014Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion.Authorship 1703773Authorship 2499278Authorship 3604467Authorship 4202681Authorship 4306821Authorship 3320035Authorship 335002Authorship 747089224899199Hu Z, Kuritzkes DRJournal of virologyAltered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors. J Virol. 2014 Aug; 88(16):9268-76.J Virol2014-06-04T00:00:002014Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.Authorship 7551351625047577Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DRAnnals of internal medicineAntiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 02; 161(5):319-27.Ann Intern Med2014-09-02T00:00:002014Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.Authorship 5721246Authorship 3635663Authorship 3755662Authorship 762150725285539Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JSAnnals of internal medicineEfficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71.Ann Intern Med2014-10-07T00:00:002014Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.Authorship 41823711Authorship 4341195Authorship 4346717Authorship 955061324699164Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJAntiviral therapyPhylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. Antivir Ther. 2015; 20(1):73-6.Antivir Ther2014-04-04T00:00:002014Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.Authorship 4238646Authorship 3705405Authorship 3729475Authorship 4372283Authorship 4590392Authorship 77528914Authorship 7748741025254301Li JZ, Heisey A, Ahmed H, Wang H, Zheng L, Carrington M, Wrin T, Schooley RT, Lederman MM, Kuritzkes DRAIDS (London, England)Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS. 2014 Nov 28; 28(18):2649-57.AIDS2014-11-28T00:00:002014Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.25502811Huang SW, Wang SF, Lin YT, Yen CH, Lee CH, Wong WW, Tsai HC, Yang CJ, Hu BS, Lin YH, Wang CT, Wang JJ, Hu Z, Kuritzkes DR, Chen YH, Chen YMPloS onePatients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression. PLoS One. 2014; 9(12):e114441.PLoS One2014-12-11T00:00:002014Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression.Authorship 5703945Authorship 572406Authorship 5584503Authorship 943846Authorship 2596838Authorship 5137935Authorship 4005855Authorship 5533079Authorship 6925612Authorship 3930077Authorship 4333232Authorship 42286514Authorship 3379043Authorship 4353079Authorship 3524822Authorship 1710735Authorship 5136977Authorship 5347781Authorship 1651812Authorship 5418827Authorship 2412467Authorship 967015Authorship 25552110Authorship 54416613Authorship 5449502Authorship 52616017Authorship 56257510Authorship 57525810Authorship 1756416Authorship 2412592Authorship 2295551Authorship 2529436Authorship 2905228Authorship 2931582Authorship 20947212Authorship 38661011Authorship 2597022Authorship 2091469Authorship 3166975Authorship 3170355Authorship 1217219Authorship 2124362Authorship 3005811Authorship 3170711Authorship 3499225Authorship 38000610Authorship 382156Authorship 4180824Authorship 4931091Authorship 3415183Authorship 3430685Authorship 2306541Authorship 3893131Authorship 3909271Authorship 5692425Authorship 2427482Authorship 2838218Authorship 290991Authorship 2927363Authorship 3180935Authorship 3196305Authorship 3683243Authorship 3737625Authorship 4163154Authorship 31119017Authorship 273614Authorship 2187855Authorship 2964481Authorship 3034076Authorship 4640171Authorship 4726314Authorship 4793357Authorship 4928995Authorship 2783271Authorship 4663312Authorship 3328511Authorship 5180166Authorship 5376301Authorship 552224Authorship 7919083Authorship 79934810Authorship 8074177Authorship 7897778Authorship 8070349Authorship 7949769Authorship 7924899Authorship 79342110Authorship 793369626046668Shafiee H, Kanakasabapathy MK, Juillard F, Keser M, Sadasivam M, Yuksekkaya M, Hanhauser E, Henrich TJ, Kuritzkes DR, Kaye KM, Demirci UScientific reportsPrinted Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva. Sci Rep. 2015 Jun 05; 5:9919.Sci Rep2015-06-05T00:00:002015Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva.25730507Henrich TJ, Hanhauser E, Hu Z, Stellbrink HJ, Noah C, Martin JN, Deeks SG, Kuritzkes DR, Pereyra FAIDS (London, England)Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 ?32. AIDS. 2015 May 15; 29(8):867-76.AIDS2015-05-15T00:00:002015Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 ?32.25285557Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JSAnnals of internal medicineSummaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2014 Oct 07; 161(7):I-22.Ann Intern Med2014-10-07T00:00:002014Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.25767256Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JSClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaComparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 06 15; 60(12):1842-51.Clin Infect Dis2015-03-12T00:00:002015Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.25884005Li JZ, Arnold KB, Lo J, Dugast AS, Plants J, Ribaudo HJ, Cesa K, Heisey A, Kuritzkes DR, Lauffenburger DA, Alter G, Landay A, Grinspoon S, Pereyra FOpen forum infectious diseasesDifferential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis. 2015 Jan; 2(1):ofu117.Open Forum Infect Dis2015-01-13T00:00:002015Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics.25743880Shafiee H, Asghar W, Inci F, Yuksekkaya M, Jahangir M, Zhang MH, Durmus NG, Gurkan UA, Kuritzkes DR, Demirci UScientific reportsPaper and flexible substrates as materials for biosensing platforms to detect multiple biotargets. Sci Rep. 2015 Mar 06; 5:8719.Sci Rep2015-03-06T00:00:002015Paper and flexible substrates as materials for biosensing platforms to detect multiple biotargets.25734091Henrich TJ, McLaren PJ, Rao SS, Lin NH, Hanhauser E, Giguel F, Gulick RM, Ribaudo H, de Bakker PI, Kuritzkes DROpen forum infectious diseasesGenome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infect Dis. 2014 Mar; 1(1):ofu018.Open Forum Infect Dis2014-05-22T00:00:002014Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.25423597Shafiee H, Wang S, Inci F, Toy M, Henrich TJ, Kuritzkes DR, Demirci UAnnual review of medicineEmerging technologies for point-of-care management of HIV infection. Annu Rev Med. 2015; 66:387-405.Annu Rev Med2014-11-12T00:00:002014Emerging technologies for point-of-care management of HIV infection.Authorship 9382216Authorship 3379723Authorship 3501465Authorship 3538975Authorship 2630663Authorship 3041149Authorship 40163610Authorship 4390126Authorship 463256Authorship 5066615Authorship 5242203Authorship 530646Authorship 5334881Authorship 3757171Authorship 3955010Authorship 416071Authorship 5294881Authorship 5545816Authorship 5770549Authorship 286162426195743Inci F, Filippini C, Baday M, Ozen MO, Calamak S, Durmus NG, Wang S, Hanhauser E, Hobbs KS, Juillard F, Kuang PP, Vetter ML, Carocci M, Yamamoto HS, Takagi Y, Yildiz UH, Akin D, Wesemann DR, Singhal A, Yang PL, Nibert ML, Fichorova RN, Lau DT, Henrich TJ, Kaye KM, Schachter SC, Kuritzkes DR, Steinmetz LM, Gambhir SS, Davis RW, Demirci UProceedings of the National Academy of Sciences of the United States of AmericaMultitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics. Proc Natl Acad Sci U S A. 2015 Aug 11; 112(32):E4354-63.Proc Natl Acad Sci U S A2015-07-20T00:00:002015Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics.Authorship 318282Authorship 816724126204597Kuritzkes DRJournal watch. AIDS clinical careReport from the 2012 International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. J Watch AIDS Clin Care. 2012 Aug; 24(8):63-5.J Watch AIDS Clin Care2012-08-01T00:00:002012Report from the 2012 International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies.Authorship 3931042Authorship 82362227Authorship 4462869Authorship 5346974Authorship 5379286Authorship 5424731Authorship 5590711Authorship 694635Authorship 3925526Authorship 840601426430882McCausland MR, Juchnowski SM, Zidar DA, Kuritzkes DR, Andrade A, Sieg SF, Lederman MM, Funderburg NTPloS oneAltered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy. PLoS One. 2015; 10(10):e0139474.PLoS One2015-10-02T00:00:002015Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.Authorship 417584526588174Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RTAIDS (London, England)The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016 Jan 28; 30(3):343-53.AIDS2016-01-28T00:00:002016The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.Authorship 847010626558541Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RMAIDS (London, England)Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS. 2015 Nov 28; 29(18):2419-26.AIDS2015-11-28T00:00:002015Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).Authorship 5229829Authorship 5141007Authorship 52466911Authorship 8606917Authorship 86217911Authorship 8705788Authorship 869069126494772Scully E, Lockhart A, Huang L, Robles Y, Becerril C, Romero-Tejeda M, Albrecht MA, Palmer CD, Bosch RJ, Altfeld M, Kuritzkes DR, Lin NHThe Journal of infectious diseasesElevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men. J Infect Dis. 2016 Mar 01; 213(5):771-5.J Infect Dis2015-10-22T00:00:002015Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men.26512140Henrich TJ, Hanhauser E, Harrison LJ, Palmer CD, Romero-Tejeda M, Jost S, Bosch RJ, Kuritzkes DRThe Journal of infectious diseasesCCR5-?32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy. J Infect Dis. 2016 Mar 01; 213(5):766-70.J Infect Dis2015-10-28T00:00:002015CCR5-?32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.26731468Kuritzkes DRThe Journal of clinical investigationHematopoietic stem cell transplantation for HIV cure. J Clin Invest. 2016 Feb; 126(2):432-7.J Clin Invest2016-01-05T00:00:002016Hematopoietic stem cell transplantation for HIV cure.Authorship 804319Authorship 29952811Authorship 3129412Authorship 875086726807968Casadellà M, Noguera-Julian M, Sunpath H, Gordon M, Rodriguez C, Parera M, Kuritzkes DR, Marconi VC, Paredes RAIDS (London, England)Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing. AIDS. 2016 Apr 24; 30(7):1137-40.AIDS2016-04-24T00:00:002016Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.Authorship 879020527119536Hill AL, Rosenbloom DI, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, Henrich TJPLoS pathogensReal-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathog. 2016 04; 12(4):e1005535.PLoS Pathog2016-04-27T00:00:002016Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.Authorship 4606857Authorship 4949812Authorship 53704513Authorship 5478819Authorship 885117827128349Zhang J, Gao X, Martin J, Rosa B, Chen Z, Mitreva M, Henrich T, Kuritzkes D, Ratner LVirologyEvolution of coreceptor utilization to escape CCR5 antagonist therapy. Virology. 2016 07; 494:198-214.Virology2016-04-26T00:00:002016Evolution of coreceptor utilization to escape CCR5 antagonist therapy.Authorship 57062510Authorship 887135526910502Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZJournal of acquired immune deficiency syndromes (1999)Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. J Acquir Immune Defic Syndr. 2016 07 01; 72(3):310-3.J Acquir Immune Defic Syndr2016-07-01T00:00:002016Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.Authorship 787182Authorship 5480531Associate Professor0Full Professor5Other FacultyAuthorship 8931761127428434Lin N, Gonzalez OA, Registre L, Becerril C, Etemad B, Lu H, Wu X, Lockman S, Essex M, Moyo S, Kuritzkes DR, Sagar MEBioMedicineHumoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine. 2016 Jun; 8:237-247.EBioMedicine2016-05-05T00:00:002016Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.Authorship 8953821127400264Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack JNature medicineInternational AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016 08; 22(8):839-50.Nat Med2016-07-11T00:00:002016International AIDS Society global scientific strategy: towards an HIV cure 2016.Authorship 534316Authorship 5607496Authorship 47727262021-01-31LICHTERFELD, MATHIAS2015-02-15A Pilot Clinical Trial for HIV-1 EradicationU01AI1178412007-07-14KURITZKES, DANIEL R2003-07-01Fitness of Enfuvirtide-(T-20)-Resistant HIV-1R01AI0553572006-05-31KURITZKES, DANIEL R1998-01-01HIV-1 resistance to nucleoside analoguesR01AI0425672018-06-30KURITZKES, DANIEL R.2003-04-01HIV-1 Resistance to Chemokine Receptor AntagonistsR37AI0553572021-05-31SHAPIRO, ROGER L2014-07-01Early Infant TreatmentU01AI1142351998-11-30KURITZKES, DANIEL R1992-12-01HIV-1-SPECIFIC CTLS IN PERINATALLY EXPOSED CHILDRENR29AI0332992014-11-30KURITZKES, DANIEL R.2007-02-01Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTUUM1AI0694722019-07-31KURITZKES, DANIEL R.2013-08-01Antiretroviral drug resistance in KwaZulu NatalR01AI0985582010-03-31GOTTLIEB, GARY L1984-12-01General Clinical Research CenterM01RR0026352011-07-31KURITZKES, DANIEL R.2001-06-01HIV-1 Therapeutics and Drug ResistanceK24RR0164822025-07-31KURITZKES, DANIEL R.1990-08-01Multidisciplinary AIDS Training ProgramT32AI0073872013-05-31KURITZKES, DANIEL R2006-06-29AIDS Clinical Trials Group NetworkU01AI0686362027-11-30CURRIER, JUDITH S. ;ERON, JOSEPH J2006-06-29AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related InfectionsUM1AI0686361994-03-31KURITZKES, DANIEL R1989-04-01HIV EPITOPES RECOGNIZED BY CYTOTOXIC T LYMPHOCYTESK11AI0009292010-03-31KRUGMAN, RICHARD D1978-12-01General Clinical Research CenterM01RR0000511996-12-311994-01-01CORE--DEVELOPMENT AND DELIVERY OF RIBOZYMES TO INHIBIT HIVU01AI0352262027-11-30BADEN, LINDSEY ROBERT;KURITZKES, DANIEL R. ;MAYER, KENNETH H2007-01-15Boston HIV CTUUM1AI0694122006-12-31KURITZKES, DANIEL R1986-06-30AIDS CLINICAL TRIALS UNITU01AI0276592013-11-30KURITZKES, DANIEL R2007-02-01Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTUU01AI0694722012-05-31KURITZKES, DANIEL R.2009-06-19V3 loop characterization by ultradeep sequencing during CCR5 antagonist therapyR21AI0774691993-09-29PIERSON, DOROTHY E1979-04-01TWO INVASINS OF YERSINIA ENTEROCOLITICAL, IN PATHOGENESIS PROCESSS07RR005357Principal InvestigatorPrincipal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorCo-Principal InvestigatorCo-Principal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorAuthorship 633204Authorship 6030614Authorship 779451Authorship 4064812Authorship 9226497Authorship 9251783Authorship 9277046Authorship 9287216Authorship 926345615826302Baird HA, Marozsan AJ, Lederman MM, Landay A, Mildvan D, Kuritzkes DR, Kessler HA, Arts EJAIDS research and therapyMonitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther. 2005 Apr 12; 2(1):2.AIDS Res Ther2005-04-12T00:00:002005Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen.26979419Landovitz RJ, Tran TT, Cohn SE, Ofotokun I, Godfrey C, Kuritzkes DR, Lennox JL, Currier JS, Ribaudo HJAIDS and behaviorHIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav. 2016 12; 20(12):2983-2995.AIDS Behav2016-12-01T00:00:002016HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States.27740536Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, Lederman MM, Mehta NNAntiviral therapyTreatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antivir Ther. 2017; 22(1):71-75.Antivir Ther2016-10-14T00:00:002016Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.24478824Wang S, Ip A, Xu F, Giguel FF, Moon S, Akay A, Kuritzkes DR, Demirci UProceedings of SPIE--the International Society for Optical EngineeringDevelopment of a microfluidic system for measuring HIV-1 viral load. Proc SPIE Int Soc Opt Eng. 2010 May 05; 7666:76661H.Proc SPIE Int Soc Opt Eng2010-05-05T00:00:002010Development of a microfluidic system for measuring HIV-1 viral load.20442796Kitchen CM, Kroll J, Kuritzkes DR, Bloomquist E, Deeks SG, Suchard MAComputational statistics & data analysisTwo-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment. Comput Stat Data Anal. 2009 Jan 15; 53(3):766-775.Comput Stat Data Anal2009-01-15T00:00:002009Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment.Authorship 5424418Authorship 547376527845796Safavieh M, Kaul V, Khetani S, Singh A, Dhingra K, Kanakasabapathy MK, Draz MS, Memic A, Kuritzkes DR, Shafiee HNanoscalePaper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens. Nanoscale. 2017 Feb 02; 9(5):1852-1861.Nanoscale2017-02-02T00:00:002017Paper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens.Authorship 5721899Authorship 9298236Authorship 936012927668293Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DCPathogens & immunityA Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016; 1(1):154-164.Pathog Immun2016-01-01T00:00:002016A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?Authorship 825278Authorship 928621Authorship 995092Authorship 19816816Authorship 1998213Authorship 2234983Authorship 27139811Authorship 2935837Authorship 3053175Authorship 3066753Authorship 5757035Authorship 656247Authorship 868967Authorship 958718127273887Kuritzkes DRJournal of medical ethicsWhy cure, why now? J Med Ethics. 2017 02; 43(2):67-70.J Med Ethics2016-06-07T00:00:002016Why cure, why now?8843206Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn JThe Journal of infectious diseasesAssociation of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct; 174(4):704-12.J Infect Dis1996-10-01T00:00:001996Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.8769604Uherova P, Connick E, MaWhinney S, Schlichtemeier R, Schooley RT, Kuritzkes DRThe Journal of infectious diseasesIn vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1. J Infect Dis. 1996 Sep; 174(3):483-9.J Infect Dis1996-09-01T00:00:001996In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1.8784610Shafer RW, Winters MA, Mayers DL, Japour AJ, Kuritzkes DR, Weislow OS, White F, Erice A, Sannerud KJ, Iversen A, Pena F, Dimitrov D, Frenkel LM, Reichelderfer PSJournal of clinical microbiologyInterlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group. J Clin Microbiol. 1996 Jul; 34(7):1849-53.J Clin Microbiol1996-07-01T00:00:001996Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group.8843205Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CSThe Journal of infectious diseasesPrognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996 Oct; 174(4):696-703.J Infect Dis1996-10-01T00:00:001996Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.10077169Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DRJournal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology AssociationClinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 01; 20(3):220-7.J Acquir Immune Defic Syndr Hum Retrovirol1999-03-01T00:00:001999Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases.10188657Tack PC, Bremer JW, Harris AA, Landay AL, Kessler HA, Kuritzkes DRJAMAGenotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. JAMA. 1999 Mar 24-31; 281(12):1085-6.JAMA1999-03-01T00:00:001999Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures.10878069Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Martinez-Picado J, Sutton L, Hazelwood JD, D'Aquila RTJournal of clinical microbiologyComparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 2000 Jul; 38(7):2715-21.J Clin Microbiol2000-07-01T00:00:002000Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.11018852Gilbert PB, Hanna GJ, De Gruttola V, Martinez-Picado J, Kuritzkes DR, Johnson VA, Richman DD, D'Aquila RTAIDS research and human retrovirusesComparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens. AIDS Res Hum Retroviruses. 2000 Sep 20; 16(14):1325-36.AIDS Res Hum Retroviruses2000-09-20T00:00:002000Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens.15456077Brun-Vézinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola VAntiviral therapyClinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004 Aug; 9(4):465-78.Antivir Ther2004-08-01T00:00:002004Clinically validated genotype analysis: guiding principles and statistical concerns.9649560Badley AD, Dockrell DH, Algeciras A, Ziesmer S, Landay A, Lederman MM, Connick E, Kessler H, Kuritzkes D, Lynch DH, Roche P, Yagita H, Paya CVThe Journal of clinical investigationIn vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998 Jul 01; 102(1):79-87.J Clin Invest1998-07-01T00:00:001998In vivo analysis of Fas/FasL interactions in HIV-infected patients.10364500Günthard HF, Leigh-Brown AJ, D'Aquila RT, Johnson VA, Kuritzkes DR, Richman DD, Wong JK, D'aquila RTVirologyHigher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. Virology. 1999 Jun 20; 259(1):154-65.Virology1999-06-20T00:00:001999Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol.10720511Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD, D'Aquila RTThe Journal of infectious diseasesPatterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis. 2000 Mar; 181(3):904-11.J Infect Dis2000-03-01T00:00:002000Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.12682150Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd RM, Reid C, Morgan GF, Winslow DLJournal of clinical microbiologyPerformance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol. 2003 04; 41(4):1594-9.J Clin Microbiol2003-04-01T00:00:002003Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.12737637Kuritzkes DRAIDS patient care and STDsHIV/AIDS salvage therapy. Interview by Vicki Glaser. AIDS Patient Care STDS. 2003 Apr; 17(4):141-5.AIDS Patient Care STDS2003-04-01T00:00:002003HIV/AIDS salvage therapy. Interview by Vicki Glaser.15356821Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaWhen more is less. Clin Infect Dis. 2004 Aug 15; 39(4):559-60.Clin Infect Dis2004-07-30T00:00:002004When more is less.118757Ruch FE, Kuritzkes DR, Lin ECBiochemical and biophysical research communicationsUse of lac operon fusions to isolate Escherichia coli mutants with altered expression of the fumarate reductase system in response to substrate and respiratory controls. Biochem Biophys Res Commun. 1979 Dec 28; 91(4):1365-70.Biochem Biophys Res Commun1979-12-28T00:00:001979Use of lac operon fusions to isolate Escherichia coli mutants with altered expression of the fumarate reductase system in response to substrate and respiratory controls.9652425Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler HThe Journal of infectious diseasesImmunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.J Infect Dis1998-07-01T00:00:001998Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.Authorship 9598811Authorship 9598781012717052D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USADrug Resistance Mutations in HIV-1. Top HIV Med. 2002 Nov-Dec; 10(5):21-25.Top HIV Med2002-11-01T00:00:002002Drug Resistance Mutations in HIV-1.11504480Kuritzkes DRDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyRecent developments in HIV-1 drug resistance. Drug Resist Updat. 1999 Apr; 2(2):127-129.Drug Resist Updat1999-04-01T00:00:001999Recent developments in HIV-1 drug resistance.10607683Campbell TB, Sevin A, Coombs RW, Peterson GC, Rosandich M, Kuritzkes DR, Mladenovic J, Landay A, Wong R, Ambruso D, Miles S, Pomerantz RJ, Schooley RTBloodChanges in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood. 2000 Jan 01; 95(1):48-55.Blood2000-01-01T00:00:002000Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team.16958560Tsibris AM, Kuritzkes DRAnnual review of medicineChemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med. 2007; 58:445-59.Annu Rev Med2007-01-01T00:00:002007Chemokine antagonists as therapeutics: focus on HIV-1.17496561Hu Z, Hatano H, Hammond SP, Smith D, Wild M, Gupta S, Whitcomb J, Kalayjian RC, Gripshover B, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. J Acquir Immune Defic Syndr. 2007 Aug 15; 45(5):494-500.J Acquir Immune Defic Syndr2007-08-15T00:00:002007Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.19915448Paredes R, Cheng I, Kuritzkes DR, Tuomala REAIDS (London, England)Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS. 2010 Jan 02; 24(1):45-53.AIDS2010-01-02T00:00:002010Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.14518706Bartlett JA, Tebas P, Bassett R, Huang W, Kuritzkes D, Reisler R, Loyack N, Robison KAntiviral therapyEarly intensification with abacavir in subjects at high risk for incomplete viral suppression. Antivir Ther. 2003 Aug; 8(4):361-3.Antivir Ther2003-08-01T00:00:002003Early intensification with abacavir in subjects at high risk for incomplete viral suppression.15795303Sharkey M, Triques K, Kuritzkes DR, Stevenson MJournal of virologyIn vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol. 2005 Apr; 79(8):5203-10.J Virol2005-04-01T00:00:002005In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.12487386Ickovics JR, Cameron A, Zackin R, Bassett R, Chesney M, Johnson VA, Kuritzkes DRAntiviral therapyConsequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther. 2002 Sep; 7(3):185-93.Antivir Ther2002-09-01T00:00:002002Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.12594310Kuritzkes DR, Currier JThe New England journal of medicineCardiovascular risk factors and antiretroviral therapy. N Engl J Med. 2003 Feb 20; 348(8):679-80.N Engl J Med2003-02-20T00:00:002003Cardiovascular risk factors and antiretroviral therapy.15097303Kuritzkes DR, Bassett RL, Hazelwood JD, Barrett H, Rhodes RA, Young RK, Johnson VAJournal of acquired immune deficiency syndromes (1999)Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr. 2004 May 01; 36(1):600-3.J Acquir Immune Defic Syndr2004-05-01T00:00:002004Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.16123676Lu J, Whitcomb J, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness. J Acquir Immune Defic Syndr. 2005 Sep 01; 40(1):20-3.J Acquir Immune Defic Syndr2005-09-01T00:00:002005Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.16280694Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MPJournal of acquired immune deficiency syndromes (1999)Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005 Dec 01; 40(4):404-12.J Acquir Immune Defic Syndr2005-12-01T00:00:002005Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.16954280Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DRJournal of clinical microbiologyPerformance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J Clin Microbiol. 2006 Sep; 44(9):3384-7.J Clin Microbiol2006-09-01T00:00:002006Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.10068575Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DRThe Journal of infectious diseasesTreatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999 Apr; 179(4):808-16.J Infect Dis1999-04-01T00:00:001999Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.10606095Spear GT, Olinger G, Sullivan BL, Landay AL, Kessler H, Connick E, Kuritzkes D, St Clair M, Spritzler J, Wu H, Lederman MMAIDS research and human retrovirusesAlteration of complement protein levels after antiretroviral therapy in HIV-infected persons. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1713-5.AIDS Res Hum Retroviruses1999-12-10T00:00:001999Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.10815085Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DDJAMAAntiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000 May 10; 283(18):2417-26.JAMA2000-05-10T00:00:002000Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.9456256Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP, Rich WJ, Jacobson MAAIDS (London, England)Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS. 1998 Jan 01; 12(1):65-74.AIDS1998-01-01T00:00:001998Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group.1373751Zhang XQ, Yang L, Ho DD, Kuritzkes DR, Chen IS, Ching WT, Chen YM, Schooley RTThe Journal of infectious diseasesHuman T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping. J Infect Dis. 1992 May; 165(5):805-12.J Infect Dis1992-05-01T00:00:001992Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping.12830416Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DDClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAntiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003 Jul 01; 37(1):113-28.Clin Infect Dis2003-06-23T00:00:002003Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.15751760Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR, Raffi FAntiviral therapyChallenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antivir Ther. 2005; 10(1):13-28.Antivir Ther2005-01-01T00:00:002005Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.10596031Kuritzkes DRJournal of hematotherapy & stem cell researchClinical experience with Filgrastim in AIDS. J Hematother Stem Cell Res. 1999; 8 Suppl 1:S17-9.J Hematother Stem Cell Res1999-01-01T00:00:001999Clinical experience with Filgrastim in AIDS.10669331Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MMThe Journal of infectious diseasesEffect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J Infect Dis. 2000 Feb; 181(2):491-7.J Infect Dis2000-02-01T00:00:002000Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.10997401Gilbert PB, Ribaudo HJ, Greenberg L, Yu G, Bosch RJ, Tierney C, Kuritzkes DRAIDS (London, England)Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial. AIDS. 2000 Sep 08; 14(13):1961-72.AIDS2000-09-08T00:00:002000Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.11114828Picchio GR, Valdez H, Sabbe R, Landay AL, Kuritzkes DR, Lederman MM, Mosier DEJournal of acquired immune deficiency syndromes (1999)Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr. 2000 Dec 01; 25(4):289-95.J Acquir Immune Defic Syndr2000-12-01T00:00:002000Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy.21124866Vaidya NK, Rong L, Marconi VC, Kuritzkes DR, Deeks SG, Perelson ASPLoS computational biologyTreatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol. 2010 Nov 24; 6(11):e1001012.PLoS Comput Biol2010-11-24T00:00:002010Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load.12759894Kosmiski LA, Kuritzkes DR, Sharp TA, Hamilton JT, Lichtenstein KA, Mosca CL, Grunwald GK, Eckel RH, Hill JOMetabolism: clinical and experimentalTotal energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism. 2003 May; 52(5):620-5.Metabolism2003-05-01T00:00:002003Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.10416520Patki AH, Purvis SF, Valdez H, Spritzler J, Connick E, Kuritzkes DR, Kessler H, Fox L, St Clair M, Landay A, Lederman MMAIDS (London, England)HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. AIDS. 1999 Jul 09; 13(10):1177-85.AIDS1999-07-09T00:00:001999HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication.10671324Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaNeutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis. 2000 Feb; 30(2):256-60.Clin Infect Dis2000-02-01T00:00:002000Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor.11176916Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DRJAMAVirologic and regimen termination surrogate end points in AIDS clinical trials. JAMA. 2001 Feb 14; 285(6):777-84.JAMA2001-02-14T00:00:002001Virologic and regimen termination surrogate end points in AIDS clinical trials.15905684Cohan D, Feakins C, Wara D, Petru A, McNicholl I, Schillinger D, Lu J, Kuritzkes D, Deeks SGAIDS (London, England)Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS. 2005 Jun 10; 19(9):989-90.AIDS2005-06-10T00:00:002005Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.12682149Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Reid C, Morgan GF, Winslow DLJournal of clinical microbiologyAccuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol. 2003 04; 41(4):1586-93.J Clin Microbiol2003-04-01T00:00:002003Accuracy of the TRUGENE HIV-1 genotyping kit.15322488Lange JM, Perriens J, Kuritzkes D, Zewdie DAIDS (London, England)What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection. AIDS. 2004 Jun; 18 Suppl 3:S69-74.AIDS2004-06-01T00:00:002004What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection.10202843Shapiro HM, Lederman M, Connick E, Kessler H, Kuritzkes DR, Landay ALAIDS (London, England)Small differences in CD4+ T-cell production may go unnoticed. AIDS. 1999 Feb 04; 13(2):290-1.AIDS1999-02-04T00:00:001999Small differences in CD4+ T-cell production may go unnoticed.10708053Kuritzkes DR, Shugarts D, Bakhtiari M, Poticha D, Johnson J, Rubin M, Gingeras TR, Kennedy M, Eron JJJournal of acquired immune deficiency syndromes (1999)Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. J Acquir Immune Defic Syndr. 2000 Jan 01; 23(1):26-34.J Acquir Immune Defic Syndr2000-01-01T00:00:002000Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.9140265McDonald CK, Kuritzkes DRArchives of internal medicineHuman immunodeficiency virus type 1 protease inhibitors. Arch Intern Med. 1997 May 12; 157(9):951-9.Arch Intern Med1997-05-12T00:00:001997Human immunodeficiency virus type 1 protease inhibitors.18419495Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, Carpenter S, Giddy J, Ross D, Holst H, Losina E, Walker BD, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPrevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008 May 15; 46(10):1589-97.Clin Infect Dis2008-05-15T00:00:002008Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.20397305Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, Gordon M, Ross D, Ewusi AD, Matthews LT, Kuritzkes DR, Marconi VCAIDS (London, England)Outcomes after virologic failure of first-line ART in South Africa. AIDS. 2010 Apr 24; 24(7):1007-12.AIDS2010-04-24T00:00:002010Outcomes after virologic failure of first-line ART in South Africa.Authorship 9841761928529033Yucha RW, Hobbs KS, Hanhauser E, Hogan LE, Nieves W, Ozen MO, Inci F, York V, Gibson EA, Thanh C, Shafiee H, El Assal R, Kiselinova M, Robles YP, Bae H, Leadabrand KS, Wang S, Deeks SG, Kuritzkes DR, Demirci U, Henrich TJEBioMedicineHigh-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. EBioMedicine. 2017 Jun; 20:217-229.EBioMedicine2017-05-04T00:00:002017High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.14703938Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Preventing and managing resistance in the clinical setting. J Acquir Immune Defic Syndr. 2003 Oct 01; 34 Suppl 2:S103-10.J Acquir Immune Defic Syndr2003-10-01T00:00:002003Preventing and managing resistance in the clinical setting.14722894Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, Reimann KA, Larson JL, Yarbough PO, Curt V, Shanahan WRThe Journal of infectious diseasesAntiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis. 2004 Jan 15; 189(2):286-91.J Infect Dis2004-01-08T00:00:002004Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.15516709Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the drug resistance mutations in HIV-1: 2004. Top HIV Med. 2004 Oct-Nov; 12(4):119-24.Top HIV Med2004-10-01T00:00:002004Update of the drug resistance mutations in HIV-1: 2004.15529271Kuritzkes DRThe Journal of infectious diseasesQuantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction. J Infect Dis. 2004 Dec 01; 190(11):2047-54.J Infect Dis2004-12-01T00:00:002004Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction.12713059Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel RAntiviral therapyAdipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther. 2003 Feb; 8(1):9-15.Antivir Ther2003-02-01T00:00:002003Adipocyte-derived hormone levels in HIV lipodystrophy.12728868Kuritzkes DR, Boyle BA, Gallant JE, Squires KE, Zolopa AThe AIDS readerCurrent management challenges in HIV: antiretroviral resistance. AIDS Read. 2003 Mar; 13(3):133-5, 138-42.AIDS Read2003-03-01T00:00:002003Current management challenges in HIV: antiretroviral resistance.12876334Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAQuestions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Top HIV Med. 2003 Jul-Aug; 11(4):150-4.Top HIV Med2003-07-01T00:00:002003Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.21949166Kuritzkes DRArchives of internal medicineHAART for HIV-1 infection: zeroing in on when to start: comment on "Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters". Arch Intern Med. 2011 Sep 26; 171(17):1569-70.Arch Intern Med2011-09-26T00:00:002011HAART for HIV-1 infection: zeroing in on when to start: comment on "Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters".16905783Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DRJAMAThree- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006 Aug 16; 296(7):769-81.JAMA2006-08-16T00:00:002006Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.17205477Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DRThe Journal of infectious diseasesInterruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis. 2007 Feb 01; 195(3):387-91.J Infect Dis2006-12-21T00:00:002006Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.17245230Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RMJournal of acquired immune deficiency syndromes (1999)Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):540-50.J Acquir Immune Defic Syndr2007-04-15T00:00:002007Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).17926654Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, Sommadossi JPAntiviral therapyIntracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther. 2007; 12(6):981-6.Antivir Ther2007-01-01T00:00:002007Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.17695089Kuritzkes DRAIDS clinical careReport from the XVI International HIV Drug Resistance Workshop. AIDS Clin Care. 2007 Aug; 19(8):69-70.AIDS Clin Care2007-08-01T00:00:002007Report from the XVI International HIV Drug Resistance Workshop.17720996Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007 Aug-Sep; 15(4):119-25.Top HIV Med2007-08-01T00:00:002007Update of the drug resistance mutations in HIV-1: 2007.18419537Ribaudo HJ, Kuritzkes DR, Lalama CM, Schouten JT, Schackman BR, Acosta EP, Gulick RMThe Journal of infectious diseasesEfavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis. 2008 Apr 01; 197(7):1006-10.J Infect Dis2008-04-01T00:00:002008Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.12869833Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, Florence E, Connick E, Smith KY, Colebunders RL, Landay A, Kuritzkes DR, Lederman MM, Vanham G, Quiñones-Mateu MEJournal of acquired immune deficiency syndromes (1999)Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr. 2003 Aug 01; 33(4):448-60.J Acquir Immune Defic Syndr2003-08-01T00:00:002003Role of Baseline pol Genotype in HIV-1 Fitness Evolution.15216459Campbell TB, Rapaport E, Schooley RT, Kuritzkes DRThe Journal of infectious diseasesIncreased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis. 2004 Jul 15; 190(2):257-66.J Infect Dis2004-06-22T00:00:002004Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim.9756769Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR, Markowitz MAntimicrobial agents and chemotherapyGenotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother. 1998 Oct; 42(10):2637-44.Antimicrob Agents Chemother1998-10-01T00:00:001998Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.18269317Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RMThe Journal of infectious diseasesPreexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008 Mar 15; 197(6):867-70.J Infect Dis2008-03-15T00:00:002008Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.15322484Kuritzkes DRAIDS (London, England)Extending antiretroviral therapy to resource-poor settings: implications for drug resistance. AIDS. 2004 Jun; 18 Suppl 3:S45-8.AIDS2004-06-01T00:00:002004Extending antiretroviral therapy to resource-poor settings: implications for drug resistance.11590531Kuritzkes DRHIV clinical trialsSelected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois. HIV Clin Trials. 2001 May-Jun; 2(3):219-26.HIV Clin Trials2001-05-01T00:00:002001Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois.19508158Kuritzkes DRThe Journal of infectious diseasesInterleukin-2: trials and tribulations. J Infect Dis. 2009 Jul 15; 200(2):164-5.J Infect Dis2009-07-15T00:00:002009Interleukin-2: trials and tribulations.19967805Kuritzkes DRThe AIDS readerEffect of antiretroviral resistance on response in treatment-experienced patients. AIDS Read. 2003 Dec; 13(12 Suppl Antiretroviral):S5-11.AIDS Read2003-12-01T00:00:002003Effect of antiretroviral resistance on response in treatment-experienced patients.23055720Wang S, Sarenac D, Chen MH, Huang SH, Giguel FF, Kuritzkes DR, Demirci UInternational journal of nanomedicineSimple filter microchip for rapid separation of plasma and viruses from whole blood. Int J Nanomedicine. 2012; 7:5019-28.Int J Nanomedicine2012-09-17T00:00:002012Simple filter microchip for rapid separation of plasma and viruses from whole blood.20672447Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RMJournal of acquired immune deficiency syndromes (1999)Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2010 Aug; 54(5):470-6.J Acquir Immune Defic Syndr2010-08-01T00:00:002010Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.15122517Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay AThe Journal of infectious diseasesImmunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004 May 15; 189(10):1811-20.J Infect Dis2004-04-29T00:00:002004Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.15353982Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, Kuritzkes D, Gross BH, Francis IR, McCune JM, Kessler H, Lederman MAIDS (London, England)Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS. 2004 Sep 24; 18(14):1953-6.AIDS2004-09-24T00:00:002004Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy.15577413Eron JJ, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, Kuritzkes DR, St Clair MH, Johnson VAJournal of acquired immune deficiency syndromes (1999)Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr. 2004 Dec 15; 37(5):1581-3.J Acquir Immune Defic Syndr2004-12-15T00:00:002004Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.Authorship 9958045Authorship 9964291328683094Hill AL, Rosenbloom DIS, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, Henrich TJPLoS pathogensCorrection: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathog. 2017 Jul; 13(7):e1006488.PLoS Pathog2017-07-06T00:00:002017Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.28702612Kanakasabapathy MK, Pandya HJ, Draz MS, Chug MK, Sadasivam M, Kumar S, Etemad B, Yogesh V, Safavieh M, Asghar W, Li JZ, Tsibris AM, Kuritzkes DR, Shafiee HLab on a chipRapid, label-free CD4 testing using a smartphone compatible device. Lab Chip. 2017 08 22; 17(17):2910-2919.Lab Chip2017-08-22T00:00:002017Rapid, label-free CD4 testing using a smartphone compatible device.16964830Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DRAntiviral therapyAmdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23.Antivir Ther2006-01-01T00:00:002006Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).17062652Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JAScience (New York, N.Y.)A plea for justice for jailed medical workers. Science. 2006 Nov 10; 314(5801):924-5.Science2006-10-24T00:00:002006A plea for justice for jailed medical workers.18181693Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RTThe Journal of infectious diseasesAntiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007 Dec 01; 196 Suppl 3:S449-56.J Infect Dis2007-12-01T00:00:002007Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.19239354Tenorio AR, Jiang H, Zheng Y, Bastow B, Kuritzkes DR, Bartlett JA, Deeks SG, Landay AL, Riddler SAAIDS research and human retrovirusesDelaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.AIDS Res Hum Retroviruses2009-02-01T00:00:002009Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.19372841Plank RM, Kuritzkes DRCurrent opinion in HIV and AIDSAn update on HIV-1 antiretroviral resistance. Curr Opin HIV AIDS. 2006 Sep; 1(5):417-23.Curr Opin HIV AIDS2006-09-01T00:00:002006An update on HIV-1 antiretroviral resistance.20071999Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner CJournal of acquired immune deficiency syndromes (1999)Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). J Acquir Immune Defic Syndr. 2010 Apr; 53(5):598-605.J Acquir Immune Defic Syndr2010-04-01T00:00:002010Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).20148638Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR, Langer R, von Andrian U, Farokhzad OCNanomedicine (London, England)Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond). 2010 Feb; 5(2):269-85.Nanomedicine (Lond)2010-02-01T00:00:002010Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.6363389Kuritzkes DR, Zhang XY, Lin ECJournal of bacteriologyUse of phi(glp-lac) in studies of respiratory regulation of the Escherichia coli anaerobic sn-glycerol-3-phosphate dehydrogenase genes (glpAB). J Bacteriol. 1984 Feb; 157(2):591-8.J Bacteriol1984-02-01T00:00:001984Use of phi(glp-lac) in studies of respiratory regulation of the Escherichia coli anaerobic sn-glycerol-3-phosphate dehydrogenase genes (glpAB).16809307Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DRJournal of virologyFitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol. 2006 Jul; 80(14):7020-7.J Virol2006-07-01T00:00:002006Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.18441382Johnson VA, Brun-Vezinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008 Apr-May; 16(1):62-8.Top HIV Med2008-04-01T00:00:002008Update of the drug resistance mutations in HIV-1: Spring 2008.19947830Walensky RP, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaThe impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential. Clin Infect Dis. 2010 Jan 15; 50(2):272-5.Clin Infect Dis2010-01-15T00:00:002010The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential.22391989Wang S, Esfahani M, Gurkan UA, Inci F, Kuritzkes DR, Demirci ULab on a chipEfficient on-chip isolation of HIV subtypes. Lab Chip. 2012 Apr 21; 12(8):1508-15.Lab Chip2012-03-06T00:00:002012Efficient on-chip isolation of HIV subtypes.22892875Kuritzkes DRArchives of internal medicineAn Abundance of Choices: Comment on "Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes". Arch Intern Med. 2012 Sep 24; 172(17):1321-3.Arch Intern Med2012-09-24T00:00:002012An Abundance of Choices: Comment on "Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes".20504163Henrich TJ, Ribaudo HJ, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaInstantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. Clin Infect Dis. 2010 Jul 01; 51(1):93-8.Clin Infect Dis2010-07-01T00:00:002010Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.Authorship 100149917Authorship 100656114Authorship 1003715428753637Paredes R, Tzou PL, van Zyl G, Barrow G, Camacho R, Carmona S, Grant PM, Gupta RK, Hamers RL, Harrigan PR, Jordan MR, Kantor R, Katzenstein DA, Kuritzkes DR, Maldarelli F, Otelea D, Wallis CL, Schapiro JM, Shafer RWPloS oneCollaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One. 2017; 12(7):e0181357.PLoS One2017-07-28T00:00:002017Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.28678879Cardozo EF, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RMPLoS pathogensTreatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. PLoS Pathog. 2017 Jul; 13(7):e1006478.PLoS Pathog2017-07-05T00:00:002017Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration.28838149Henrich TJ, Hobbs KS, Hanhauser E, Scully E, Hogan LE, Robles YP, Leadabrand KS, Marty FM, Palmer CD, Jost S, Körner C, Li JZ, Gandhi RT, Hamdan A, Abramson J, LaCasce AS, Kuritzkes DRThe Journal of infectious diseasesHuman Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. J Infect Dis. 2017 07 15; 216(2):254-262.J Infect Dis2017-07-15T00:00:002017Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.19479085Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DRPloS oneQuantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One. 2009 May 25; 4(5):e5683.PLoS One2009-05-25T00:00:002009Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.21857490Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJAIDS (London, England)Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011 Nov 13; 25(17):2113-22.AIDS2011-11-13T00:00:002011Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).15980332Miranda LR, Götte M, Liang F, Kuritzkes DRAntimicrobial agents and chemotherapyThe L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother. 2005 Jul; 49(7):2648-56.Antimicrob Agents Chemother2005-07-01T00:00:002005The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.7814561Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DRJournal of clinical microbiologyStandardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol. 1994 Sep; 32(9):2291-4.J Clin Microbiol1994-09-01T00:00:001994Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.7856987D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DDAnnals of internal medicineZidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15; 122(6):401-8.Ann Intern Med1995-03-15T00:00:001995Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.7930716McFarland EJ, Harding PA, Luckey D, Conway B, Young RK, Kuritzkes DRThe Journal of infectious diseasesHigh frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection. J Infect Dis. 1994 Oct; 170(4):766-74.J Infect Dis1994-10-01T00:00:001994High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection.9647263McFarland EJ, Harding PA, MaWhinney S, Schooley RT, Kuritzkes DRJournal of immunology (Baltimore, Md. : 1950)In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children. J Immunol. 1998 Jul 01; 161(1):513-9.J Immunol1998-07-01T00:00:001998In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children.11404514Lu J, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants. J Acquir Immune Defic Syndr. 2001 May 01; 27(1):7-13.J Acquir Immune Defic Syndr2001-05-01T00:00:002001A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants.12733606Kuritzkes DRJournal of HIV therapyResistance to protease inhibitors. J HIV Ther. 2002 Nov; 7(4):87-91.J HIV Ther2002-11-01T00:00:002002Resistance to protease inhibitors.15322476Zewdie D, Lange J, Kuritzkes DAIDS (London, England)Rapid expansion of access to antiretroviral therapy (ART). AIDS. 2004 Jun; 18 Suppl 3:S1-3.AIDS2004-06-01T00:00:002004Rapid expansion of access to antiretroviral therapy (ART).16304457Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med. 2005 Oct-Nov; 13(4):125-31.Top HIV Med2005-10-01T00:00:002005Update of the drug resistance mutations in HIV-1: Fall 2005.17209769Kitchen CM, Lu J, Suchard MA, Hoh R, Martin JN, Kuritzkes DR, Deeks SGAIDS research and human retrovirusesContinued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1260-6.AIDS Res Hum Retroviruses2006-12-01T00:00:002006Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.17310819Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RMAntiviral therapyDesign issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther. 2006; 11(6):751-60.Antivir Ther2006-01-01T00:00:002006Design issues in initial HIV-treatment trials: focus on ACTG A5095.18073450Kuritzkes DRTopics in HIV medicine : a publication of the International AIDS Society, USAHIV resistance: frequency, testing, mechanisms. Top HIV Med. 2007 Nov-Dec; 15(5):150-4.Top HIV Med2007-11-01T00:00:002007HIV resistance: frequency, testing, mechanisms.19467854Moon S, Keles HO, Ozcan A, Khademhosseini A, Haeggstrom E, Kuritzkes D, Demirci UBiosensors & bioelectronicsIntegrating microfluidics and lensless imaging for point-of-care testing. Biosens Bioelectron. 2009 Jul 15; 24(11):3208-14.Biosens Bioelectron2009-04-02T00:00:002009Integrating microfluidics and lensless imaging for point-of-care testing.20048714Lin NH, Kuritzkes DRCurrent opinion in HIV and AIDSTropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS. 2009 Nov; 4(6):481-7.Curr Opin HIV AIDS2009-11-01T00:00:002009Tropism testing in the clinical management of HIV-1 infection.28761901Piantadosi A, Mukerji SS, Chitneni P, Cho TA, Cosimi LA, Hung DT, Goldberg MB, Sabeti PC, Kuritzkes DR, Grad YHOpen forum infectious diseasesMetagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis. Open Forum Infect Dis. 2017; 4(3):ofx138.Open Forum Infect Dis2017-07-28T00:00:002017Metagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis.22954962Lin NH, Becerril C, Giguel F, Novitsky V, Moyo S, Makhema J, Essex M, Lockman S, Kuritzkes DR, Sagar MVirologyEnv sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology. 2012 Nov 25; 433(2):296-307.Virology2012-09-03T00:00:002012Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.22974526Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DRJournal of virological methodsLow-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods. 2012 Dec; 186(1-2):68-72.J Virol Methods2012-09-04T00:00:002012Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR.23460751Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DRThe Journal of infectious diseasesLong-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 01; 207(11):1694-702.J Infect Dis2013-03-04T00:00:002013Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.Authorship 1016617728973412Godfrey C, Thigpen MC, Crawford KW, Jean-Phillippe P, Pillay D, Persaud D, Kuritzkes DR, Wainberg M, Raizes E, Fitzgibbon JThe Journal of infectious diseasesGlobal HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation. J Infect Dis. 2017 12 01; 216(suppl_9):S798-S800.J Infect Dis2017-12-01T00:00:002017Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.10546781Young B, Kuritzkes DRAIDS (London, England)Viral kinetics: implications for treatment. AIDS. 1999 Sep; 13 Suppl 1:S11-7.AIDS1999-09-01T00:00:001999Viral kinetics: implications for treatment.10608760Smith KY, Valdez H, Landay A, Spritzler J, Kessler HA, Connick E, Kuritzkes D, Gross B, Francis I, McCune JM, Lederman MMThe Journal of infectious diseasesThymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis. 2000 Jan; 181(1):141-7.J Infect Dis2000-01-01T00:00:002000Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.11709791Connick E, Schlichtemeier RL, Purner MB, Schneider KM, Anderson DM, MaWhinney S, Campbell TB, Kuritzkes DR, Douglas JM, Judson FN, Schooley RTThe Journal of infectious diseasesRelationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. J Infect Dis. 2001 Dec 01; 184(11):1465-9.J Infect Dis2001-11-13T00:00:002001Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion.12435711Stoeckli TC, MaWhinney S, Uy J, Duan C, Lu J, Shugarts D, Kuritzkes DRAntimicrobial agents and chemotherapyPhenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother. 2002 Dec; 46(12):4000-3.Antimicrob Agents Chemother2002-12-01T00:00:002002Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.12637625Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo MThe New England journal of medicineEnfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003 May 29; 348(22):2175-85.N Engl J Med2003-03-13T00:00:002003Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.12838743Kuritzkes DRThe AIDS readerManagement of patients with virologic and metabolic failure. AIDS Read. 2003 Jun; 13(6 Suppl):S17-22.AIDS Read2003-06-01T00:00:002003Management of patients with virologic and metabolic failure.14513420Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, DeGruttola VThe Journal of infectious diseasesAssessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003 Oct 01; 188(7):1001-8.J Infect Dis2003-09-23T00:00:002003Assessing resistance costs of antiretroviral therapies via measures of future drug options.14724329Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USADrug resistance mutations in HIV-1. Top HIV Med. 2003 Nov-Dec; 11(6):215-21.Top HIV Med2003-11-01T00:00:002003Drug resistance mutations in HIV-1.16825395Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JWJournal of clinical microbiologyBlinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol. 2006 Jul; 44(7):2612-4.J Clin Microbiol2006-07-01T00:00:002006Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.12837968D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USADrug resistance mutations in HIV-1. Top HIV Med. 2003 May-Jun; 11(3):92-6.Top HIV Med2003-05-01T00:00:002003Drug resistance mutations in HIV-1.15983922Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DRClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAntiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis. 2005 Jul 15; 41(2):236-42.Clin Infect Dis2005-06-07T00:00:002005Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.16267755Kuritzkes DRThe Journal of infectious diseasesLess than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. J Infect Dis. 2005 Dec 01; 192(11):1867-8.J Infect Dis2005-10-25T00:00:002005Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.17147496De Gruttola V, Flexner C, Schapiro J, Hughes M, Van Der Laan M, Kuritzkes DRAIDS research and human retrovirusesDrug development strategies for salvage therapy: conflicts and solutions. AIDS Res Hum Retroviruses. 2006 Nov; 22(11):1106-9.AIDS Res Hum Retroviruses2006-11-01T00:00:002006Drug development strategies for salvage therapy: conflicts and solutions.17570119Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DRThe Journal of infectious diseasesPhase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007 Jul 15; 196(2):304-12.J Infect Dis2007-06-05T00:00:002007Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.18814368Kuritzkes DRAIDS clinical careReport from the XVII International HIV Drug Resistance Workshop. AIDS Clin Care. 2008 Aug; 20(8):61-2.AIDS Clin Care2008-08-01T00:00:002008Report from the XVII International HIV Drug Resistance Workshop.19385087Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, Saag M, Squires KE, Weddle A, Rainey J, Zerehi MR, Ralston JF, Fleming DA, Bronson D, Cooke M, Cutler C, Ejnes Y, Gluckman R, Liebow M, Musana K, Mayer ME, Purtle MW, Reynolds PP, Viswanathan L, Weiss KB, Yehia BClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaHIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis. 2009 May 15; 48(10):1335-44.Clin Infect Dis2009-05-15T00:00:002009HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians.19494074Hosoya N, Su Z, Wilkin T, Gulick RM, Flexner C, Hughes MD, Skolnik PR, Giguel F, Greaves WL, Coakley E, Kuritzkes DRJournal of clinical microbiologyAssessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions. J Clin Microbiol. 2009 Aug; 47(8):2604-6.J Clin Microbiol2009-06-03T00:00:002009Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.20121419Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RMClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaSubstitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010 Mar 01; 50(5):787-91.Clin Infect Dis2010-03-01T00:00:002010Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.18786985Murphy RA, France H, Sunpath H, Gordon ML, Marconi VC, Kuritzkes DR, McIntosh KJournal of tropical pediatricsDevelopment of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa. J Trop Pediatr. 2009 Feb; 55(1):60-2.J Trop Pediatr2008-09-11T00:00:002008Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa.21245516Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010 Dec; 18(5):156-63.Top HIV Med2010-12-01T00:00:002010Update of the drug resistance mutations in HIV-1: December 2010.22692090Murphy RA, Sunpath H, Castilla C, Ebrahim S, Court R, Nguyen H, Kuritzkes D, Marconi VC, Nachega JBJournal of acquired immune deficiency syndromes (1999)Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr. 2012 Oct 01; 61(2):158-163.J Acquir Immune Defic Syndr2012-10-01T00:00:002012Second-line antiretroviral therapy: long-term outcomes in South Africa.Authorship 10227161429098203Belury MA, Bowman E, Gabriel J, Snyder B, Kulkarni M, Palettas M, Mo X, Lake JE, Zidar D, Sieg SF, Rodriguez B, Playford MP, Andrade A, Kuritzkes DR, Mehta NN, Lederman MM, Funderburg NTPathogens & immunityProspective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. Pathog Immun. 2017; 2(3):376-403.Pathog Immun2017-10-06T00:00:002017Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV.1775869Nitta AT, Kuritzkes DRReviews of infectious diseasesPyomyositis due to group C streptococci in a patient with AIDS. Rev Infect Dis. 1991 Nov-Dec; 13(6):1254-5.Rev Infect Dis1991-11-01T00:00:001991Pyomyositis due to group C streptococci in a patient with AIDS.9030363Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, Johnson J, Keller A, Hill AMAIDS (London, England)Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. AIDS. 1997 Feb; 11(2):169-75.AIDS1997-02-01T00:00:001997Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.9030393Kuritzkes DRAIDS (London, England)Clinical significance of drug resistance in HIV-1 infection. AIDS. 1996 Dec; 10 Suppl 5:S27-31.AIDS1996-12-01T00:00:001996Clinical significance of drug resistance in HIV-1 infection.15483465Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, Fichtenbaum CJ, Pettinelli C, Neath D, Ferguson E, Saah AJ, Gerber JGJournal of acquired immune deficiency syndromes (1999)Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr. 2004 Nov 01; 37(3):1358-66.J Acquir Immune Defic Syndr2004-11-01T00:00:002004Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.Authorship 10245322229112956Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SGPLoS medicineHIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med. 2017 Nov; 14(11):e1002417.PLoS Med2017-11-07T00:00:002017HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.16392089Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis. 2006 Feb 01; 42(3):401-7.Clin Infect Dis2005-12-27T00:00:002005Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.3536878Iuchi S, Kuritzkes DR, Lin ECJournal of bacteriologyThree classes of Escherichia coli mutants selected for aerobic expression of fumarate reductase. J Bacteriol. 1986 Dec; 168(3):1415-21.J Bacteriol1986-12-01T00:00:001986Three classes of Escherichia coli mutants selected for aerobic expression of fumarate reductase.11600828Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RHAIDS (London, England)Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS. 2001 Oct 19; 15(15):1993-2000.AIDS2001-10-19T00:00:002001Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.11717419Kuritzkes DRProceedings of the National Academy of Sciences of the United States of AmericaA fossil record of zidovudine resistance in transmitted isolates of HIV-1. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13485-7.Proc Natl Acad Sci U S A2001-11-20T00:00:002001A fossil record of zidovudine resistance in transmitted isolates of HIV-1.15380959Youle M, Cohen C, Katlama C, Kuritzkes D, Walmsley SLancet (London, England)Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Lancet. 2004 Sep 18-24; 364(9439):1036-7.Lancet2004-09-01T00:00:002004Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.20863238Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJAIDS research and human retrovirusesChange in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011 May; 27(5):461-8.AIDS Res Hum Retroviruses2010-11-23T00:00:002010Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.8517697Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RTAntimicrobial agents and chemotherapyStandardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother. 1993 May; 37(5):1095-101.Antimicrob Agents Chemother1993-05-01T00:00:001993Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.Authorship 10291581929174084Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio SThe lancet. HIVCost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018 03; 5(3):e146-e154.Lancet HIV2017-11-22T00:00:002017Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.22164225Tsibris AM, Pal U, Schure AL, Veazey RS, Kunstman KJ, Henrich TJ, Klasse PJ, Wolinsky SM, Kuritzkes DR, Moore JPPloS oneSHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS One. 2011; 6(12):e28047.PLoS One2011-12-02T00:00:002011SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.16280695Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MPJournal of acquired immune deficiency syndromes (1999)Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005 Dec 01; 40(4):413-21.J Acquir Immune Defic Syndr2005-12-01T00:00:002005Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.17197813Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett DAIDS (London, England)HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007 Jan 11; 21(2):215-23.AIDS2007-01-11T00:00:002007HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.3182995Ruoff KL, Kuritzkes DR, Wolfson JS, Ferraro MJJournal of clinical microbiologyVancomycin-resistant gram-positive bacteria isolated from human sources. J Clin Microbiol. 1988 Oct; 26(10):2064-8.J Clin Microbiol1988-10-01T00:00:001988Vancomycin-resistant gram-positive bacteria isolated from human sources.22739389Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa MY, Ordonez C, Kuritzkes DR, Marconi VCAIDS (London, England)High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS. 2012 Aug 24; 26(13):1679-84.AIDS2012-08-24T00:00:002012High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.23028623Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath HPloS oneCoadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. PLoS One. 2012; 7(9):e44793.PLoS One2012-09-28T00:00:002012Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.17662474Paredes R, Marconi VC, Campbell TB, Kuritzkes DRJournal of virological methodsSystematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods. 2007 Dec; 146(1-2):136-46.J Virol Methods2007-07-26T00:00:002007Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.2310182Stinson MC, Galanek MS, Ducatman AM, Masse FX, Kuritzkes DRApplied and environmental microbiologyModel for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a BL3 facility. Appl Environ Microbiol. 1990 Jan; 56(1):264-8.Appl Environ Microbiol1990-01-01T00:00:001990Model for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a BL3 facility.Authorship 10315074Authorship 1034386129206998Kuritzkes DRThe Journal of infectious diseasesIn Memoriam: Mark A. Wainberg. J Infect Dis. 2017 Dec 01; 216(suppl_9):S797.J Infect Dis2017-12-01T00:00:002017In Memoriam: Mark A. Wainberg.29220839Murphy RA, Marconi VC, Gandhi RT, Kuritzkes DR, Sunpath HPloS oneCorrection: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa. PLoS One. 2013; 8(12).PLoS One2013-12-09T00:00:002013Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa.21754988Moon S, Gurkan UA, Blander J, Fawzi WW, Aboud S, Mugusi F, Kuritzkes DR, Demirci UPloS oneEnumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLoS One. 2011; 6(7):e21409.PLoS One2011-07-06T00:00:002011Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients.18495779Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DRJournal of virologyIn vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol. 2008 Aug; 82(16):8210-4.J Virol2008-05-21T00:00:002008In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.20479938Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, Markowitz M, Little S, Sax PE, Collier AC, Nabel G, Saindon S, Flynn T, Kuritzkes D, Barouch DHPloS oneSafety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One. 2010 May 10; 5(5):e10555.PLoS One2010-05-10T00:00:002010Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.21288812Kuritzkes DRThe Journal of infectious diseasesGenotypic tests for determining coreceptor usage of HIV-1. J Infect Dis. 2011 Jan 15; 203(2):146-8.J Infect Dis2010-12-08T00:00:002010Genotypic tests for determining coreceptor usage of HIV-1.22357810Kuritzkes DR, Hakim JG, Sanne IClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaLeast among equals. Clin Infect Dis. 2012 Mar; 54(6):876-7.Clin Infect Dis2012-03-01T00:00:002012Least among equals.3479685Pomerantz RJ, Kuritzkes DR, de la Monte SM, Rota TR, Baker AS, Albert D, Bor DH, Feldman EL, Schooley RT, Hirsch MSThe New England journal of medicineInfection of the retina by human immunodeficiency virus type I. N Engl J Med. 1987 Dec 24; 317(26):1643-7.N Engl J Med1987-12-24T00:00:001987Infection of the retina by human immunodeficiency virus type I.65 Landsdowne Street, room 449Brigham & Women's HospitalInfectious Disease65 Landsdowne Street, room 449Cambridge02139MA19339945Kuritzkes DRCurrent opinion in HIV and AIDSHIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS. 2009 Mar; 4(2):82-7.Curr Opin HIV AIDS2009-03-01T00:00:002009HIV-1 entry inhibitors: an overview.20856130Henrich TJ, Tsibris AM, Lewine NR, Konstantinidis I, Leopold KE, Sagar M, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr. 2010 Dec; 55(4):420-7.J Acquir Immune Defic Syndr2010-12-01T00:00:002010Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.8853730Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA, Rubin MAIDS (London, England)Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS. 1996 Aug; 10(9):975-81.AIDS1996-08-01T00:00:001996Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.Authorship 1038852829333522Park YJ, Etemad B, Ahmed H, Naranbhai V, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Carrington M, Li JZPathogens & immunityImpact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathog Immun. 2017; 2(3):431-445.Pathog Immun2017-11-27T00:00:002017Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.18572749Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, Hoh R, Liegler T, Spudich S, Kuritzkes DR, Deeks SGAntiviral therapyEnfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther. 2008; 13(3):369-74.Antivir Ther2008-01-01T00:00:002008Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.18645515Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin JN, Deeks SG, Kuritzkes DRJournal of acquired immune deficiency syndromes (1999)Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. J Acquir Immune Defic Syndr. 2008 Aug 15; 48(5):572-6.J Acquir Immune Defic Syndr2008-08-15T00:00:002008Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.7680062McFarland EJ, Curiel TJ, Schoen DJ, Rosandich ME, Schooley RT, Kuritzkes DRThe Journal of infectious diseasesCytotoxic T lymphocyte lines specific for human immunodeficiency virus type 1 Gag and reverse transcriptase derived from a vertically infected child. J Infect Dis. 1993 Mar; 167(3):719-23.J Infect Dis1993-03-01T00:00:001993Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type 1 Gag and reverse transcriptase derived from a vertically infected child.8673545Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn JJournal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology AssociationPhase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 01; 12(4):363-70.J Acquir Immune Defic Syndr Hum Retrovirol1996-08-01T00:00:001996Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team.19015347Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis STAntimicrobial agents and chemotherapySafety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009 Feb; 53(2):450-7.Antimicrob Agents Chemother2008-11-17T00:00:002008Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.20599562Lin NH, Negusse DM, Beroukhim R, Giguel F, Lockman S, Essex M, Kuritzkes DRJournal of virological methodsThe design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods. 2010 Oct; 169(1):39-46.J Virol Methods2010-06-25T00:00:002010The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates.Authorship 1042280921326075Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM, Kuritzkes DRAIDS (London, England)Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS. 2011 Mar 13; 25(5):665-9.AIDS2011-03-13T00:00:002011Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.23228784Kuritzkes DJournal of the International AIDS SocietyProgress in HIV vaccine research: an outsider's view. J Int AIDS Soc. 2012; 15(6):18190.J Int AIDS Soc2012-11-11T00:00:002012Progress in HIV vaccine research: an outsider's view.9182469Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RTAnnals of internal medicineMonitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997 Jun 15; 126(12):929-38.Ann Intern Med1997-06-15T00:00:001997Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.Authorship 107449711181147Gulick RM, Smeaton LM, D'Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi JP, Tung R, Snyder S, Kuritzkes DR, Murphy RLThe Journal of infectious diseasesIndinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J Infect Dis. 2001 Mar 01; 183(5):715-21.J Infect Dis2001-01-30T00:00:002001Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.12351945Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay AAIDS (London, England)Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS. 2002 Sep 27; 16(14):1859-66.AIDS2002-09-27T00:00:002002Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.12859322Kosmiski L, Kuritzkes D, Hamilton J, Sharp T, Lichtenstien K, Hill J, Eckel RHIV medicineFat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome. HIV Med. 2003 Jul; 4(3):235-40.HIV Med2003-07-01T00:00:002003Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome.15849371Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A, Richman DTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med. 2005 Mar-Apr; 13(1):51-7.Top HIV Med2005-03-01T00:00:002005Update of the Drug Resistance Mutations in HIV-1: 2005.16946457Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DDTopics in HIV medicine : a publication of the International AIDS Society, USAUpdate of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006 Aug-Sep; 14(3):125-30.Top HIV Med2006-08-01T00:00:002006Update of the drug resistance mutations in HIV-1: Fall 2006.22491471Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DRJournal of virologyVicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures. J Virol. 2012 Jun; 86(12):6416-26.J Virol2012-04-04T00:00:002012Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.23166820Henrich TJ, Wood BR, Kuritzkes DRPloS oneIncreased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. PLoS One. 2012; 7(11):e50065.PLoS One2012-11-15T00:00:002012Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.23217792Orrell C, Levison J, Ciaranello A, Bekker L, Kuritzkes D, Freedberg K, Wood RJournal of the International AIDS SocietyEvolution of resistance in paediatric patients with failure on antiretroviral therapy. J Int AIDS Soc. 2012; 15(6):18086.J Int AIDS Soc2012-11-11T00:00:002012Evolution of resistance in paediatric patients with failure on antiretroviral therapy.3055187Kuritzkes DR, Rein M, Horowitz S, Droege G, Waldron MA, Bell DA, Fuller AF, Ellman LL, Dickersin GR, Swartz MNReviews of infectious diseasesDetached ciliary tufts mistaken for peritoneal parasites: a warning. Rev Infect Dis. 1988 Sep-Oct; 10(5):1044-7.Rev Infect Dis1988-09-01T00:00:001988Detached ciliary tufts mistaken for peritoneal parasites: a warning.2023-01-31KURITZKES, DANIEL R.;LICHTERFELD, MATHIAS ;SHAPIRO, ROGER L2018-02-20A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940Co-Principal Investigator9643863Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DDJAMAAntiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998 Jun 24; 279(24):1984-91.JAMA1998-06-24T00:00:001998Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.10413649Kaushal S, Landay AL, Lederman MM, Connick E, Spritzler J, Kuritzkes DR, Kessler H, Levine BL, St Louis DC, June CHClinical immunology (Orlando, Fla.)Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol. 1999 Jul; 92(1):14-24.Clin Immunol1999-07-01T00:00:001999Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells.1466371Nitta AT, Madinger NE, Kuritzkes DRThe American journal of medicinePyomyositis due to catalase-negative organism in patient with AIDS. Am J Med. 1992 Dec; 93(6):705.Am J Med1992-12-01T00:00:001992Pyomyositis due to catalase-negative organism in patient with AIDS.7477218Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin MThe New England journal of medicineTreatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995 Dec 21; 333(25):1662-9.N Engl J Med1995-12-21T00:00:001995Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.7524542Kuritzkes DR, Bell S, Bakhtiari MAIDS (London, England)Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1. AIDS. 1994 Jul; 8(7):1017-9.AIDS1994-07-01T00:00:001994Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.